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Soluplus is a suitable excipient for innovative manufacturing techniques such as hot-melt 
extrusion (HME). While Soluplus is useful for forming amorphous solid dispersions (ASD’s) 
during HME, the resulting extrudates are often stiff and brittle. In order to achieve suitable 
dosage forms, with optimal downstream processability, an efficient screening for suitable 
formulations is required. Vacuum compression moulding (VCM) is a rapid, cost-efficient 
sample preparation method for thermoplastic materials that could possibly be used as a reliable 
screening tool.  
Solid dispersions with 10%, 30% and 50% w/w drug load of naproxen (NAP) or celecoxib 
(CCX) in Soluplus were prepared by HME and VCM under controlled conditions (HME: 
120°C, 0 and 5 min recirculation, 50RPM, VCM: 120°C, 15 min). Melt processability and the 
effect of drug load were evaluated using rheology, subjecting the samples to a frequency sweep 
from 100-0.01 Hz at 120°C within the linear viscoelastic region. The samples were also 
analysed using differential scanning calorimetry (DSC), polarized light microscopy (PLM) and 
Raman Spectroscopy. The stability during storage of the solid dispersions prepared using HME 
was also investigated. 
 
The complex viscosity (ƞ*) between the different preparative methods varied considerably 
especially at the higher drug-loads. The lack of mixing and shear forces in VCM leads to less 
amorphisation and higher crystal content of drug in the mixture, which increases the melt 
viscosity. The difference is especially evident at higher drug loads where the mixing is critical 
for forming an ASD. The results also show that the dissolved NAP can act as a plasticizer 
lowering the melt viscosity of the API-polymer mixture. VCM should be used with 
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1 Introduction 
 
Soluplus is a polymer suitable for innovative manufacturing techniques such as hot-melt 
extrusion (HME)(Ali, Langley, Djuric, & Kolter, 2015). While Soluplus is useful for forming 
amorphous solid dispersions (ASD’s) during HME, the resulting extrudates are often stiff and 
brittle. To achieve suitable dosage forms, with optimal downstream processabilities, an efficient 
screening for suitable formulations is required. Vacuum compression moulding (VCM) is a 
rapid, cost-efficient sample preparation method for thermoplastic materials that could possibly 
be used as a reliable screening tool (Treffer, Troiss, & Khinast, 2015). 
This thesis has focused on investigating if VCM can be used as an appropriate tool for assessing 
the melt behaviour of HME formulations and as a screening tool for finding suitable 
formulations for HME. Rheological analysis, Raman spectroscopy, differential scanning 
calorimetry (DSC) and polarized light microscopy (PLM) has been evaluated as tools for 
assessing the quality and melt processability of solid dispersions prepared by HME. Naproxen 
(NAP) and celecoxib (CCX) were chosen as model compounds. Soluplus was chosen as the 
model polymer. 
 
2 Litterature review 
 
2.1 Solubility of drugs 
 
The oral route of drug administration remains the preferred and most used method due to its 
non-invasive and patient oriented nature, improving the long term compliance of patients (Shaji 
& Patole, 2008). For an oral dosage form to have a clinical effect and enter the systemic 
circulation it must pass certain barriers. First the drug must be released from the carrier system 
(for example from a tablet). Then the drug must dissolve in the gastro-intestinal (GI) fluids 
during the short timeframe the drug travels through the GI-tract. After that the dissolved drug 
must permeate through the intestinal membrane into the blood stream (Ruiz-Garcia, Bermejo, 
Moss, & Casabo, 2008). 
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2.1.1 The Biopharmaceutics Classification System 
 
The Biopharmaceutics Classification System (BCS) is a classification system suggested by 
Amidon and Lennernäs in 1995, classifying drugs into four categories based on their solubility 
and intestinal permeability (Table 1)(Amidon, Lennernäs, Shah, & Crison, 1995). The BCS has 
since been widely accepted as a guideline in lead detection and development of drugs and their 
appropriate dosage forms. The BCS has been introduced to the guidelines of the Food and Drug 
Administration (FDA) and is being used by regulatory agencies in the process of new drug 
approvals. (Löbenberg & Amidon, 2000). 
Table 1 The Biopharmeceutics Classification System 
Class Solubility Permeability 
I High High 
II Low High 
III High Low 
IV Low Low 
 
Solubility issues are affecting the bioavailability of oral drugs. For drugs in the 
biopharmaceutical classification system (BCS) class II (high permeability, low solubility) 
solubility is the limiting factor (Amidon et al., 1995). The introduction of high throughput 
screening (HTS) has led from the traditional method of drug solubilisation to a massive increase 
in screening capacity for new chemical entities (NCE). Today in vitro assays are used to screen 
for activity of compounds from large chemical libraries with hundreds of thousands of 
compounds (Mayr & Bojanic, 2009). In these libraries compounds are often dissolved in aprotic 
solvents, for example dimethyl sulfoxide (DMSO), as stock solutions. This has led to water 
solubility not being as relevant in HTS lead detection as it used to be and thus, even a higher 
percentage of lead compounds are poorly soluble in aqueous media (Burbaum, 1998). This has 
led to approximately 30-40% of marketed oral drugs with instant release profile being 
practically insoluble in water with a solubility of less than 0.01 mg/mL (Takagi et al., 2006). 
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Today, the BCS and thus, determination of in vivo solubility and permeability has been 
incorporated in HTS and lead detection by most pharmaceutical companies (Ku, 2008). 
 
2.1.2 Solubilisation techniques  
 
With increased complexity and specificity of new drugs and receptors there has been an 
increase in formulation research in delivery systems and in increasing the solubility of poorly 
water-soluble drugs (Singh, Worku, & Van den Mooter, 2011). Different solubilisation 
techniques have been developed to tackle the challenge of poorly soluble drugs. These include 
solid dispersions, cyclodextrin complexes, lipid based systems and nanocrystals  (Y. Huang & 
Dai, 2014). 
Cyclodextrins are cyclic oligosaccharides with a hydrophobic core and hydrophilic shell (Fig 
1). Cyclodextrins form complexes with hydrophobic compounds enhancing solubility and thus 
bioavailability of poorly soluble drugs (Loftsson & Duchêne, 2007).   
 
Figure 1 (a) The chemical structure and (b) the toroidal shape of the β-cyclodextrin molecule. (Loftsson & Brewster, 
1996) 
Lipid based drug delivery systems (LBBDS) for oral preparations have shown to increase 
bioavailability of poorly soluble drugs by stimulating gallbladder contractions and increasing 
secretion of bile salts and phospholipids in the GI tract. This increases solubilisation of the 
hydrophobic drug. Lipids can also increase the residence time in the GI tract (Dahan & 
Hoffman, 2008). 
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Nanocrystals are crystalline drug particles at nanoscale (<1μm). Nanocrystals can be produced 
either by precipitation techniques using solvents or by disintegration techniques such as ball 
milling (Keck & Müller, 2006).  Nanocrystals improve dissolution by the significant surface 
area enlargement according to the Noyes-Whitney equation (Noyes & Whitney, 1897). 
Nanocrystals also increase the apparent solubility, which at nanorange is also a function of 
particle size (Junghanns & Müller, 2008).  
While improving solubility using methods such as cyclodextrins, LBDDS, or surfactants these 
methods have the tendency to decrease the apparent permeability. Amorphous solid dispersions 
show a solubility enhancing effect while having limited or no effect on permeability while 
increasing the solubility (Miller, Beig, Carr, Spence, & Dahan, 2012). Within the recent years 
solid dispersion has been firmly established as a platform technology, when working with 
formulations of poorly soluble drugs.  
 
2.2 Solid dispersions 
 
Solid dispersions and especially amorphous solid dispersions (ASD’s) is a promising method 
to improve bioavailability of poorly soluble drugs. It is common census that by reducing the 
particle size of drugs, where the dissolution of the drug in the GI-tract is the limiting factor, it 
generally increases absorption and bioavailability (Fincher, 1968). Amorphous drugs have 
shown to have a higher saturation solubility compared with crystalline drugs  due to the lack of 
a crystalline lattice (Hancock & Parks, 2000). For a drug to dissolve from a crystalline state, 
energy is required. By transforming the drug to the amorphous form, it enters a higher energy 
state. As the crystalline state is a lower energy state it is the thermodynamically favoured state 
and thus amorphous compounds tend to recrystallize. ASD’s utilize an excipient, usually a 
polymer, to fix the drug in its amorphous dispersed state by hydrogen bonding and a high glass 
transition temperature (𝑇𝑔) (Yu, 2001). The glass transition can be described as the transition 
of an amorphous solid from a hard and brittle glassy state, into a rubbery viscous state (Forrest, 
Dalnoki-Veress, Stevens, & Dutcher, 1996). 
Most solid dispersions used today can be defined as dispersions of drug in an amorphous 
polymer matrix, where the drug is preferably in the molecular dispersed state. The hydrophobic 
drug is molecularly dispersed by melting or dissolving it in a hydrophilic carrier, for example 
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a polymer. At storage conditions the polymer matrix is in a solid-state, suspending the drug 
inside it (Fig 2). The solid dispersions can be prepared to oral formulations such as tablets or 
capsules (Y. Huang & Dai, 2014). 
 
Figure 2 The ideal structure of a solid dispersion where the drug (red) is molecularly dispersed in the polymer matrix 
(blue) (Y. Huang & Dai, 2014) 
In solid dispersions the drug is highly dispersed in the polymer matrix, ideally on a molecular 
level. By dispersing the drug molecules, solid dispersion systems provide a large surface area 
of the drug, which increases the dissolution rate.  By dispersing the drug in the polymer,  the 
crystalline lattice of the drug is removed and the crystal packing energy is reduced, thus 
reducing the energy required to dissolve the drug in aqueous media (Jermain, Brough, & 
Williams III, 2018). The solid dispersion contains stored potential energy that releases when 
the system gets in contact with the gastrointestinal fluids and works as a spring, producing a 
supersaturation of the drug (Jermain et al., 2018). The drug is then absorbed from the 
supersaturated state into the systemic circulation. As the supersaturation is in a 
thermodynamically unstable state, the hydrophilic carrier must work as a stabilizer or so-called 
parachute, prolonging the absorption by inhibiting precipitation of the drug in the GI-fluids for 
the time it takes to be absorbed into the body. (Brouwers, Brewster, & Augustijns, 2009; 
Guzman et al., 2007). Polymers such as polyvinylpyrrolidone (PVP), 
hydroxypropylmethylcellulose (HPMC) and poly-ethylene glycol (PEG) have shown 
stabilizing effect in solid dispersions (Jermain et al., 2018). Newman et al. (Newman, Knipp, 
& Zografi, 2012) evaluated research papers on amorphous solid dispersions and showed that in 
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Today the use of solid dispersions is an established technique to improve bioavailability with 
several products on the market (Table 2). At least three methods of producing solid dispersions 
are used in commercial products. These are hot melt extrusion (HME), spray drying, and solvent 
co-precipitation (Y. Huang & Dai, 2014). 
 
Table 2 Examples of FDA approved solid dispersions on the market (adapted from Y. Huang & Dai, 2014) 
Product 
name API Polymer 
API Tm 
(°C) SD preparation method 
Year of 
approval 
Cesamet Nabilone PVP 160   1985 
Sporanox Itraconazole HPMC 166 
Spray drying on sugar 
beads 1992 
Prograf Tacrolimos HPMC 128 Spray drying 1994 
Kaletra Lopinavir/ritonavir PVP/VA 125/122 Melt extrusion 2005 
Intelence Etravirine HPMC 265 Spray drying 2008 
Zotress Everolimus HPMC 115 Spray drying 2010 
Novir Ritonavir PVP/VA 122 Melt extrusion 2010 
Onmel Itraconazole HPMC 166 Melt extrusion 2010 
Incivek Telaprevir HPMCAS 246 Spray drying 2011 
Zelboraf Vemurafenib HPMCAS 272 Co-precipitation 2011 
Kalydeco Ivacaftor HPMCAS 291 Spray drying 2012 
 
Itraconazole is a good example of the benefits of solid dispersions. Itraconazole is a broad-
spectrum antifungal drug that is insoluble in water and was commercialized using solid 
dispersion technology. The first marketed product was Sporanox® using spray drying method 
to significantly improve the bioavailability of the drug. Later Onmel® came on the market with 
a melt extrusion formulation of itraconazole, eliminating the use of solvents and reducing the 
dosage frequency. The results of these studies and other marketed solid dispersions are 
reviewed by Jermain et al. (Jermain et al., 2018)  
Other interesting studies of possible products from solid dispersion technology include: 
Solid dispersions of rebamipide, an antiulcer drug in BCS class IV, and poloxamer showed 
improved bioavailability in rats, compared to tablets with conventional rebamipide, by 
enhancing the solubility of the drug (Tung et al., 2011). Albendazole is used to treat a variety 
of parasitic worms. Solid dispersions of albendazole, showed a 2,4-fold increase in 
bioavailability in rabbits compared to a commercial product (Kalaiselvan, Mohanta, 
Madhusudan, Manna, & Manavalan, 2007). Solid dispersion granules of curcumin showed an 
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approximately 10-fold increase in both area under the plasma concentration-time curve (AUC) 
and maximum plasma concentration (Cmax) in rats compared with curcumin (Jang, Kim, Lee, 
& Oh, 2014). An HIV-attachment inhibitor, BMS-488043 prepared into amorphous dispersion 
using spray-drying showed a 15–18-fold improvement in Cmax and 7–9-fold in AUC relative 
to a crystalline capsule formulation in dogs (Fakes et al., 2009) 
A challenge with ASD’s is that as the API is in an amorphous state, which is a metastable state 
and not as energetically favourable as the crystalline state. This leads to risk of recrystallization 
or precipitation of the API in the polymer matrix, which provides challenge for preparing 
ASD’s with reliable shelf life. ASD’s can also phase separate over time, which can lead to 
further recrystallization (Vasanthavada, Tong, Joshi, & Kislalioglu, 2005). Another challenge 
is to avoid precipitation of the drug in the GI-tract after its been released from the carrier matrix. 
 
2.2.1 Glass forming ability of amorphous drugs 
 
Amorphous drugs can be classified by assessing the glass forming ability (GFA) or the tendency 
to recrystallize. The classification system classifies amorphous drugs into three classes 
depending on the cooling rate required to inhibit recrystallization from the heated molten state 
of the drug. Class I drugs require very rapid cooling >750°C/min. Class II drugs require modest 
cooling at rates of 10-20°C/min from the molten state to recrystallize while class III drugs can 
stay amorphous at low cooling rates (approx. 1°C/min).  The model compounds used in this 
thesis are class I (naproxen) and class II (celecoxib). (Baird, Van Eerdenbrugh, & Taylor, 2010; 
Blaabjerg, Lindenberg, Löbmann, Grohganz, & Rades, 2016) 
 
2.2.2 Hot-melt Extrusion 
 
Hot-melt extrusion (HME) is a processing technique that has widely been used in the plastic, 
rubber and food industry since the 1930’s (Chokshi & Zia, 2010). The process of HME was 
originally introduced to prepare polymeric coatings for wires in the mid-nineteenth century. 
(Crowley et al., 2007). Today, a large part of all plastic products is manufactured by HME.  The 
HME technique was introduced to the pharmaceutical industry in the 1960’s  and is today an 
established method for producing different dosage forms of solid dispersions.  
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In HME the active pharmaceutical ingredient (API) and a polymer or combination of polymers 
are melted and mixed at elevated temperature. The heat combined with the shear force 
generated by the screws cause the crystalline drug to convert into amorphous form.  The 
resulting mixture is cooled and solidified before downstream processing into for example 
tablets or capsules. HME requires the API and polymer to be miscible and thermodynamically 
stable at processing parameters (temperature, shear forces, residence time) (Crowley et al., 
2007). Today many companies produce a plethora of different polymers specially designed for 
a certain manufacturing method. For example, Soluplus® by BASF 
(PEG6000/vinylcaprolactam/vinylacetate copolymer, Soluplus®, BASF, Germany) is 
especially developed for use in hot melt extrusion thanks to its suitable process behaviour. 
(Kolter, Karl, Gryczke, & Ludwigshafen am Rhein, 2012).  
The extruder consists of the feeder or hopper, a barrel with controllable conditions including 
temperature and screw speed, and a die (Fig 3). Extruders are available in single screw or multi 
screw configurations. Twin-screw extruders are the most used extruders because of their 
dispersive and distributive mixing, conveying high shear to break up particles while dispersing 
them (Wilson, Williams, Jones, & Andrews, 2012).  The two screws are usually aligned side 
by side and give the extruder configurability and improved mixing and conveying capabilities 
compared to a single-screw extruder. The screws can either be co-rotating or counter-rotating. 
(Crowley et al., 2007).   
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Figure 3 Schematic of an extruder (Patil, Tiwari, & Repka, 2016) 
 
The HME process can be divided into the following sections: 1) feeding of material into the 
extruder through the feeder, 2) melting, mixing and conveying of the melt, 3) extrusion through 
a die and 4) cooling and down-stream processing. Process parameters include flow of powder, 
shear force, residence time and pressure, cooling rate and shaping of the extrudate. HME 
requires in process monitoring of parameters such as heat, torque and pressure to ensure 
uniformity of the product. (Breitenbach, 2002). The extruder can also be equipped with in line 
monitoring such as Raman spectroscopy to monitor API concentration and solid-state 
characteristics of the API-polymer melt (Saerens et al., 2011).   
HME offers certain advantages to other manufacturing methods. HME is a relatively simple 
processing method with few processing steps. It requires no solvent in producing ASD’s and is 
suitable for continuous manufacturing at relatively high throughput rate. HME is very versatile 
with modulated extruders with customizable screws and adjustable screw speed, shear rate and 
temperature. The temperature can also be adjusted in different parts of the extruder. However, 
HME is not suitable for production of all drugs. HME is performed at elevated temperatures so 
it is not suitable for thermal sensitive drugs or excipients (Chokshi & Zia, 2010). 
The glass transition temperature (𝑇𝑔 ) affects the stability of the ASD. The 𝑇𝑔  allows the 
entrapment of the drug in the polymer in a “glassy” solid state below the 𝑇𝑔. Above the 𝑇𝑔 the 
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drug-polymer mixture enters a viscous, rubbery state. When temperature is further increased 
the viscosity lowers towards liquid-like properties. The 𝑇𝑔 should be 40-50 °C higher than the 
storage temperature (Yoshioka, Hancock, & Zografi, 1995). With a low 𝑇𝑔 the extrudate will 
be softer and more prone to recrystallization and phase separation at storage temperatures.  
BASF Pharma Polymers, producer of polymers for HME suggests that a suitable 𝑇𝑔  for 
thermoplastic polymers used in HME should be 50 – 180 °C (Kolter et al., 2012) For optimal 
melt extrusion the carrier polymer has to be workable at relatively low temperatures due to 
thermal degradation of several drugs at higher temperatures.  
During HME, polymers may be subjected to different types of degradation. Sources of 
degradation may include mechanical degradation from shear forces by the rotating screws, 
thermal degradation by the elevated process temperature and oxidative degradation. It is 
possible to stabilize polymers using antioxidants. Crowley and his co-workers (2002) states that 
Vitamin E, Vitamin E succinate and Vitamin E polyethylene glycol 1000 succinate (TPGS) 
were found to be suitable stabilizers for PEO during processing. TPGS is obtained by the 
esterification of Vitamin E succinate with polyethylene glycol 1000  (Crowley, Zhang, Koleng, 
& McGinity, 2002). HME have been used to produce granules, pellets, capsules, sustained 
release tablets, transdermal and transmucosal drug delivery systems and implants (Crowley et 
al., 2007)  
 
2.2.3 Spray drying and co-precipitation 
 
In spray drying the components are dissolved together and then dispersed into droplets by 
atomization. The droplets are rapidly dried using a hot gas, often air or nitrogen. The dried 
powder is then collected for further processing (Singh & Van den Mooter, 2016).The rapid 
evaporation during the process causes kinetic trapping of the API in the carrier matrix resulting 
in a supersaturated molecular dispersion (Paudel, Worku, Meeus, Guns, & Van den Mooter, 
2013).  
Another technique to produce solid dispersions is co-precipitation, where a non-solvent is 
added to the API and the polymeric carrier solution under mixing. The API and polymer co-
precipitate forming microparticles. The microparticles are filtered and dried for further 
processing (J. Huang, Wigent, Bentzley, & Schwartz, 2006). 
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2.2.4 Polymers in hot-melt extrusion 
 
Polymers are large molecules consisting of repeating subunits called monomers. Due to the 
macromolecular structure of polymers, containing long polymeric chains with different lengths 
and morphology, different polymers exhibit very different properties (Rudin, 1998). Polymers 
range from synthetic plastics to natural occurring polymers such as cellulose.  Polymers can 
have characteristics optimal for entrapping drugs in their amorphous state and are often used as 
the carrier matrix in the manufacturing of ASD’s. This is due to amorphous polymers having a 
glass-transition temperature (𝑇𝑔). At temperatures below the 𝑇𝑔, polymers are in a glassy, solid 
like state, where there is no mobility between the polymeric chains. At the 𝑇𝑔 of the polymer, 
it transitions from a glassy state to a rubbery state with limited mobility between the chains. As 
the temperature is further increased, the polymer transitions into a molten state with free 
mobility between chains. When the ASD’s prepared by HME are cooled below the 𝑇𝑔 of the 
drug-polymer melt, the drug becomes entrapped in the glassy state of the polymer matrix 
meaning that the drug is molecularly dispersed within the matrix.  
 
2.2.4.1 Polymeric melts 
 
 Many small-molecule drugs act as plasticizers in the polymeric melt, increasing the free 
volume and decreasing the friction between the polymer molecules. The plasticizing effect be 
observed as a decrease in 𝑇𝑔  for the API-polymer melt and a decrease in brittleness of the 
finished extrudates. (Aho, Edinger, Botker, Baldursdottir, & Rantanen, 2016)  
 
2.2.5 Advantages and limitations of solid dispersions 
 
The most obvious advantage of using solid dispersions is the improved bioavailability due to 
the improved solubility in the GI-tract. The preparation of solid dispersions using methods such 
as HME is rather simple with few processing steps. Preparation of solid dispersions using HME 
enables for continuous manufacturing, which is more economical and time saving compared to 
conventional batch by batch processing (Schaber et al., 2011). Solid dispersions can be prepared 
without solvents that can be expensive and bad for the environment. There are several ways to 
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produce solid dispersions that suits different types of drugs and excipients. Solid dispersions 
can be produced into powders, granules, pellets, films, patches and can even be molded into 
desired shapes and sizes with techniques such as injection molding and 3d-printing (Kolter et 
al., 2012) 
Recrystallization is the biggest problem of solid dispersions. Solid dispersions tend to 
recrystallize since that is the favored energy state. An inert carrier matrix with a high enough 
glass transition temperature and viscosity at storage temperature is required to avoid 
recrystallization during storage. Solid dispersions can also absorb moisture, which can result in 
phase separation and recrystallization (Vasconcelos, Sarmento, & Costa, 2007).  The 
pharmaceutical industry is still adapting to continuous manufacturing and more in-line 
analytical tools need to be developed and validated before it can be utilized fully. Analytical 
tools such as Raman spectroscopy show promise for use as process analytical tools (PAT) 
(Wahl et al., 2013). Heat sensitive drugs have a risk of degrading during processing at elevated 
temperatures. The process temperatures can be lowered by using plasticizers lowering the 
viscosity of the melt. Some drugs can work as plasticizers themselves (Repka, Gerding, Repka, 
& McGinity, 1999).  
Solid dispersions show great promise in improving bioavailability of poorly soluble drugs. 
There are several products already on the market and with the industry seemingly willing to go 
into continuous manufacturing instead of just traditional batch to batch manufacturing, solid 
dispersions (especially produced by melt extrusion) offer products that are suitable for 
continuous manufacturing and downstream processing into wanted dosage forms. The biggest 
challenge seems to be the risk of recrystallization of the drug in the carrier matrix. This can be 
reduced by polymer selection, appropriate drug loading and packaging of the product. By 
overcoming challenges of storage and process recrystallization, solid dispersions will hopefully 




The use of polymers in medicine is not new. Natural polymers have been used as components 
in traditional medicine for thousands of years (Satchi-Fainaro & Duncan, 2006). With the surge 
in polymer technology in the 20th century several synthetic polymers have become available for 
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drug development. Potential issues relating to the suitability of polymers in the development of 
nanomedicine are reviewed by Ruth Duncan (Duncan, 2011). Duncan mentions safety issues 
such as potential toxicity of polymers and their metabolites, stability during storage and 
administration (i.e. recrystallization, phase separation) and reproducibility in manufacturing in 
terms of molecular weight, branching or other forms of heterogeneity.  An issue with 
biodegradable polymers is the uncertainty of the safety of the degradation products. Especially 
at chronic use of solid dispersions it is important that the polymer is not accumulated in the 
body but is eliminated. The degradation and elimination of polymers from the body is still not 
completely certain. However, most polymers used in solid dispersions have already been 
approved by regulatory agents such as FDA and EMA and are generally regarded as safe. The 
route of administration also plays a role as for example some polymers such as PVP does not 




Rheology is the study of deformation and flow of matter (Barnes, Hutton, & Walters, 1989). In 
the food industry for example rheology is used to analyze properties such as mouth feel, 
chewability and ease to swallow (Aho, Hvidt, & Baldursdottir, 2016). To understand the flow 
properties of the polymeric melts during HME, a proper understanding of the rheological 
properties should be known (Aho, 2011).  
The framework for rheology is set by Newtons law of viscosity for Newtonian fluids and 
Hooke’s Law for ideal solids. Newtons law of viscosity states that the shear viscosity, or ratio 
of shear stress to shear rate, is constant. This law is only valid for Newtonian fluids such as for 
example water or glycerin. In contrast to Newtonian fluids, fully elastic, or ideal solid materials, 
such as metals, follow Hooke’s Law. Hooke’s Law states that the stress applied to a material  
is proportional to the strain (George & Qureshi, 2013). Ideal solids deform elastically where 
the material return to its original state after the stress is removed. Newtonian or ideal fluids 
deform irreversibly, when stress is applied they flow and do not return to the original state after 
the stress is removed. Ideal fluids follow Newton’s law and ideal solids follow Hooke’s.  
However, materials often have both solid and liquid-like properties when undergoing 
deformation. and exhibit rheological characteristics of interest. These materials are called 
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viscoelastic materials (Ferry, 1980) Rheology focuses mainly on so called non-Newtonian 
fluids. The viscosity of non-Newtonian fluids is not constant and the viscosity is dependent on 
the shear rate (George & Qureshi, 2013).  
 
Shear stress and shear rate can be described mathematically using a two-plate model as an 
example (Fig 4). Considering a sample between two plates where the upper plate is moved by 
a given force F. Shear stress, τ is defined as the force applied to the plate divided by the area of 
the plate, A (Eq 1). Using the same model shear rate, γ̇  can be defined as the velocity, v of the 
upper plate divided by the distance, h between the two plates (Eq 2).  
 
Figure 4 Visualization of the two plate model (Aho, 2011) 
 
τ =  
F
A




    (𝑠−1)        [2] 





    (𝑃𝑎 × 𝑠)       [3] 
 
The shear viscosity gives a measure of the thickness, or resistance to flow of the material. 
Polymers are viscoelastic and thus the melt properties are somewhere between those of ideal 
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liquids and ideal solids. The viscoelasticity means the material responds to stress-strain 
behavior time dependent and the deformation is partially reversible. Most polymers exhibit a 
property called shear-thinning. The viscosity decreases as a function of shear rate (Fig 5). This 
is due to the disentanglement of the entangled polymer chains (Aho, 2011). The shear thinning 
of polymers is an important characteristic during HME, where the shear forces of the screws 
together with the elevated temperature significantly lowers the viscosity of the polymer melt, 
allowing the drug to be dispersed within the polymer. 
 
Figure 5 Visualization of shear thinning. At higher shear rates a decrease in viscosity is observed (shear thinning). 
The viscosity of Newtonian fluids is not affected by the shear rate. Some materials such as slurries can exhibit 
shear thickening, where higher shear rates increases the viscosity of the melt. (May & Henderson, 2013)  
 
For reliable rheological data, the experiments should be conducted in the linear viscoelastic 
region of the polymer before plastic, irreversible deformation occurs. The linear viscoelastic 
region is the region where the deformation applied on the sample is reversible (elastic 
deformation) and the polymeric structure remains unchanged. This usually encompasses a very 
small force of deformation. Small amplitude oscillatory shear rheology is used to characterize 
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2.3.1 Small amplitude oscillatory shear rheology  
 
To better understand the properties of polymers in the viscoelastic region small amplitude 
oscillatory shear (SAOS) rheology can be used. SAOS applies a small pre-defined strain at a 
changing frequency to the sample. The viscoelasticity is measured as the phase lag between the 
applied stress and the corresponding strain. One type of SAOS measurement is the parallel-
plate model (Fig 6), where the sample is placed between two circular plates, one stationary and 
one performing oscillating strain on the sample and the resulting stress response is measured. 
It is also possible to use SAOS in stress-controlled mode where the strain response to the 
applied stress is measured. 
 
Figure 6 Schematic of a rotational parallel-plate geometry used in SAOS rheological measurements (Leizea et al., 
2017) 
 
The strain function can be described as:  
𝛾(𝑡) =  𝛾0𝑠𝑖𝑛 (𝜔𝑡)        [4] 
where 𝜔  is the angular frequency and 𝛾0  is the strain amplitude. The corresponding stress 
response can be described as:  
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𝜏 = 𝜏0sin (𝜔𝑡 + 𝛿)        [5] 
In the viscoelastic region the deformation of the sample is sinusoidal where the response of 
the material is in a lag phase behind the stress (Fig 7) The lag between stress and strain is 
defined as the phase angle, δ. The phase angle δ is related to the viscoelasticity of the sample. 
For an ideal elastic sample δ=0° and for an ideal viscous material δ=90°. A viscoelastic 
sample has a phase lag between 0° and 90°. 
 
Figure 7 The phase angle between the applied stress and the measured strain in a stress controlled SAOS 
measurement (Aho, 2011) 
From the phase angle the viscoelastic moduli can be calculated. The elastic, reversible 
characteristics are represented by the storage modulus, G', describing the amount of energy 
stored in the sample. The loss modulus G'' represents the viscous characteristics describing the 
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The complex viscosity gives an understanding of the rheological properties of the sample and 
can help to give an assessment for drug-polymer melts during HME.  
 
2.4 Vacuum compression moulding  
 
For reliable rheological results homogenous sample preparation is important. Traditionally 
samples have been prepared by compression or injection moulding. Treffer et al. have 
introduced a novel vacuum compression moulding (VCM) tool for preparing homogenous 
thermoplastic samples for rheological measurements (Treffer et al., 2015). The MeltPrep® tool 
(Fig 8) offers certain advantages such as simple, fast sample preparation at a low-cost. The 
vacuum removes excess air preventing the formation of air bubbles in the sample, which can 
lead to erroneous results when doing rheological analysis. The small chamber reduces heat load 
and mechanical stress reducing degradation. 
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Figure 8 The VCM tool (Treffer et al., 2015) 
The tool consists of a cylindrical base plate, a main body, a piston and a lid. The o-ring seals 
provide a gas-tight chamber together with the main body. The sample can be loaded into the 
chamber as a powder. The tool is then connected to a vacuum source producing a lower pressure 
than the surrounding atmospheric pressure. The vacuum forces the piston to compress the 
sample. The tool is then heated using a hot-plate. The heat melts the sample producing a 
uniform, bubble-free sample. The sample is then cooled and removed from the tool. Separation 
foils with a Polytetrafluoroethylene (PTFE) coating prevents sticking of material to the tool.  
 
2.5 Analytical methods 
 
 
2.5.1 Thermogravimetric analysis 
 
Thermogravimetric analysis (TGA) measures change in weight as a function of increasing 
temperature. A small amount of sample is placed on a tared heat resistant pan, for example 
platinum and heated up in a furnace. The weight loss of the sample is measured. The obtained 
data from the TGA can  be used to determine degradation temperature and solvent evaporation 
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2.5.2 DSC 
 
Differential Scanning Calorimetry (DSC) is a quantitative analytical method for detailed 
thermal and physical analysis of chemicals. DSC measures energy difference as a function of 
temperature or time. The difference in amount of energy required to increase the temperature 
of a sample and a reference pan is measured.  DSC can provide information such as the purity 
of a drug or phase transitions such as melting temperature. The 𝑇𝑔 of an amorphous drug can 
also be observed. In DSC the 𝑇𝑔 can be observed as a change in heat capacity and thus a change 
in the baseline can be observed in the DSC curve (Clas, Dalton, & Hancock, 1999). 
 
2.5.3 Polarized Light Microscopy 
 
Polarized Light Microscopy (PLM) is an optical microscopy method utilizing polarized light to 
detect or determine the crystallographic properties of compounds (Carlton, 2011).  Natural light 
or non-polarized light vibrates in random directions, while linear polarized light travels within 
a single plane (Fig 9). By using a polarizing filter the natural light is converted into polarized 
light by only letting through light of a single orientation (Kliger & Lewis, 2012). By using two 
perpendicular polarizing filters no light waves are let through the PLM. When a crystalline, 
birefringent sample is placed between the filters it will diffract the light. The diffracted light 
can pass the second polarizing filter and the crystals can be visualized and characterized. 
(Carlton, 2011; Wolman & Kasten, 1986) 
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Figure 9 Representation of linearly polarized light. Examples of polarization oriented along the x axis (A) or y axis 
(B) (Kliger & Lewis, 2012). 
 
2.5.4 X-ray Powder Diffraction 
 
X-ray Powder Diffraction (XRPD) is a fast, non-destructive analytical method for structural 
characterization of materials. It can be used to determine crystallographic density and the 
crystalline structure of a sample and is an effective tool for confirming amorphous structure of 
the prepared ASD’s. X-ray wavelengths are diffracted by a crystalline sample. The crystalline 
sample acts as a diffraction grating allowing the X-rays to reinforce each other by constructive 
interference, when Bragg’s law is satisfied: 
𝑛𝜆 = 2𝑑 sin (𝜃)         [10] 
Where n is an integer, λ is the wavelength of the x-ray, d is the spacing between the the planes 
of the crystalline lattice and 𝜃 is the angle of diffraction (Fig 10). The pattern of scattering is 
unique to each crystalline structure. 
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Figure 10 Bragg’s law of diffraction. X-rays diffracted by planes with the interplanar spacing d at a diffraction 
angle of θ. The lower ray travels an extra distance of 2d sin θ (Byrn, Zografi, & Chen, 2017) 
 
In XRPD the powdered sample have the crystals oriented randomly in all directions along a 
single dimension. By measuring the diffraction along this dimension, a diffractogram 
representing all crystal orientations can be observed. The x-rays are emitted at a constant 
intensity and wavelength while changing the angle θ between the sample and the source (Fig 
11).  A detector moves similarly at an angle of 2θ detecting the intensity of the diffracted x-rays.  
The resulting diffractogram is a plot of intensity as a function of 2θ (Byrn et al., 2017). 
 
 
Figure 11 Principle of the XPRD equipment. (Byrn et al., 2017) 
 
In XRPD, amorphous material tend to express a diffuse halo due to no long range order in the 
sample, while crystalline material express sharper peaks (Fig 12) (Andrews et al., 2010). 
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Figure 12 Powder X‐ray diffractometry patterns for crystalline CCX, physical mixture of crystalline CCX  and 
PVP and hot‐melt extruded samples containing amorphous CCX (Andrews et al., 2010) 
 
The XRPD is a common tool for confirming the amorphisity of ASD’s. However, the XRPD 
was unavailable during the time of this thesis. 
 
2.5.5 Raman spectroscopy 
 
Raman spectroscopy is a vibrational spectroscopy that measures the inelastic scattering of 
monochromatic light from a sample. Inelastic scattering refers to the part of scattering where 
the emitted light photon from the sample has either a higher or lower energy than the source 
photon. The light, typically from a monochromatic laser, interacts with the molecular bonds 
within the sample and excites a given bond to a temporary virtual state. The bond then scatters 
the photon back with either the same amount of energy (called Rayleigh scattering or elastic 
scattering), with a lower energy (stokes scattering) or with higher energy (anti-stokes scattering) 
(Fig 13). The inelastic stokes and anti-stokes scattered photons can then be observed with a 
detector. The energy shift of the photon gives information about vibrational modes in the 
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sample. Rayleigh scattering is the dominant form and only a small part of the scattering is 
inelastic. Approximately only one in every 106 -108 photon is inelastic or Raman active. Due 
to this weak signal from the Raman scattering the Rayleigh scattering must be filtered out using 
a filter. Raman spectroscopy also require a powerful laser to be able to detect the Raman 
scattering (Smith & Dent, 2013). 
 
Figure 13 The Rayleigh and Raman scattering presented as Stokes and anti-Stokes scattering.(Smith & Dent, 2013) 
 
Raman is a scattering technique in contrast to absorption techniques such as X-ray absorption, 
fluorescence emission and infrared (IR) absorption. In absorption techniques instead of 
scattering the photon it is absorbed and the electron/molecule is moved to an excited energy 
state, n causing vibrations in the molecules. Raman data is obtained due to the polarizability of 
the electrons in the sample molecules. After the sample has been subjected to the inelastic 
scattering, the sample enters a different rotational or vibrational state. The scattering intensity 
is proportional to the change in polarizability. The energy loss (or gain) of the scattered photon 
is characteristic for a specific bond in the molecule, thus Raman provides a structural fingerprint 
which can be used to identify the molecular structure of the sample. (Smith & Dent, 2013) 
Paired with complementary techniques such as infrared (IR) spectroscopy, Raman provides us 
with characteristics of fundamental vibrations that are extensively used in characterization of 
molecular structures. (Larkin, 2017; Smith & Dent, 2013). Raman spectroscopy can be used as 
In-line characterization tools in pharmaceutical manufacturing during for example hot melt 
extrusion to characterize the miscibility of API and polymer, as well as the 
amorphous/crystalline structure of the melt. (Saerens et al., 2011). 
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After the data has been obtained it is often necessary to apply a range of preprocessing steps to 
extract the relevant data. Standard normal variate transformation (SNV) is a common method 
for normalising the data. SNV normalizes the spectra to unit standard deviation, correcting for 
intensity of the peaks making the spectra easily comparable. 
Principal component analysis (PCA) is an eigenvalue-based statistical method for finding the 
main sources of variance a dataset, in this case the spectral data. It takes the variance between 
the observations and decomposes them into principal components, each describing the main 
sources of variation within the data. Principal component 1 (PC-1) explains the main part of the 
variance and succeeding variance is explained by PC-2, PC-3 and so forth. The level of variance 
explained is given by a percentage. PCA helps cluster the data into subgroups making it easier 
to separate the differences within the obtained data. The data are also separated into a loadings 
plot, showing the nature of the variation in the principal component. If the loadings plot of a 
PC looks similar to a feature in the spectra, it is highly likely that the principal component 
describes the variation related to that feature (eg. if the loadings plot looks similar to the 
amorphous peak, the PC likely describes the level of amorphicity within the samples) (Abdi & 
Williams, 2010). 
2.5.6 Prediction of drug-polymer solubility (Flory-Huggins model) 
 
To ensure the stability of the ASD’s during storage it is important to assess the solubility of the 
drug in the polymer. To keep the ASD stable and prevent recrystallization during shelf life, it 
is essential that the drug is molecularly dispersed below its saturation solubility allowing a 
molecularly dispersed ASD. As most relevant drugs and polymers are in the solid state or highly 
viscous state at room temperature the assessment is often carried out at higher temperatures and 
then extrapolated down to room temperature (Knopp et al., 2016) (Knopp et al., 2015). The 
Flory-Huggins model (Flory, 1953) can be used to predict the drug-polymer solubility, using a 
melting point depression for oversaturated drug-polymer ratios in the DSC.  The melting of the 
crystalline drug should occur when the chemical potential of the crystal equals the chemical 
potential of the melt. The amorphous polymer should reduce the chemical potential of the 
crystalline drug, lowering the melting point. By fitting the model by Flory-Huggins to the drug-
polymer system the melting point depression can be related to the solubility of the drug in the 
polymer (Knopp et al., 2015). Accurate, known ratios of drug-polymer are mixed gently to 
reduce particle size but to avoid amorphisation of the drug. The mixtures are slowly heated in 
 
Page 28 of 132 
the DSC. The onset of the endothermic melting of the mixture can be considered the solubility 
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  [11] 
Where ∆𝐻𝑚 is the enthalpy of fusion for the pure drug, 𝑇𝑚 is the melting temperature for the 
pure drug. R is the gas constant, λ is the molar volume ratio of the polymer and drug. χ is the 
Flory-Huggins interaction parameter. T is the onset of melting temperature. 𝑣𝑑𝑟𝑢𝑔 is the volume 









        [12] 
where 𝜌𝑑𝑟𝑢𝑔 and  𝜌𝑝𝑜𝑙𝑦𝑚𝑒𝑟 are the densities of the drug and polymer.  𝑋𝑑𝑟𝑢𝑔 is the mass 
fraction of the drug. 
The results of melt point depression at elevated temperatures can be extrapolated down to 
room temperature using a statistical model presented by Knopp et al. (Knopp et al., 2015) to 
estimate the drug solubility in the polymer at room temperature which is the preferred storage 
temperature. The estimates were reported as central estimates (the least-squares estimate) with 




The aim of this project was to investigate different preparative methods of solid dispersions to 
evaluate them as possible screening tools for the quality and melt processability of API-polymer 
mixtures. HME and VCM was chosen as the preparative methods.  
This thesis has focused on investigating if rheological analysis can be used as an appropriate 
tool for assessing the quality and melt processability of solid dispersions prepared by HME. 
The effect of drug load on rheological properties of API-polymer mixtures have also been 
investigated. VCM has been evaluated as a screening tool for HME and for assessing the 
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miscibility of drug-polymer mixtures. The suitability of VCM for finding the optimal 
temperature and process parameters for HME was evaluated. 
Different analytical methods were used for determining the physiochemical properties and 
formation of amorphous solid dispersions (ASD’s) of the prepared API-polymer mixtures 
including Raman spectroscopy, differential scanning calorimetry (DSC), thermogravimetric 
analysis (TGA) and polarized light microscopy (PLM).  The benefits of other methods such as 
X-ray powder diffraction was also discussed. The Flory-Huggins model was used to determine 
solubility of API in polymer and compared with the analytical data obtained through other 
methods. 
 
4 Materials  
4.1 Raw materials 
 
4.1.1 Naproxen  
 
Naproxen was purchased from Fagron Nordic A/S (Copenhagen, Denmark). Naproxen, (2S)-
2-(6-Methoxynaphthalen-2-yl)propanoic acid is a non-steroid anti-inflammatory drug (NSAID) 
with both antipyretic and anti-inflammatory effects and is used in treatment various pain and 
inflammatory conditions (Fig 14). Naproxen is a nonselective cyclooxygenase inhibitor (COX) 
inhibiting both enzymes COX-1 and COX-2.  (Ta & Dionne, 2004). Naproxen is practically 
insoluble in water and is soluble in ethanol.  The sodium salt of naproxen is being used 
commercially to improve water solubility. Naproxen has a melting point of 153°C. Naproxen 
is a weak acid with pKa 4.15. Naproxen is classified as class II in the BCS and as class I by 
GFA. The limiting factors for the bioavailability of Naproxen is the solubility and the 
dissolution rate. The naphthalene ring causes strong π–π interactions and the carboxylic acid 
groups form hydrogen bonds which makes naproxen very prone to recrystallization and 
amorphous naproxen is very physically unstable by itself.  (Liu, Zhou, & Zhang, 2017). 
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Celecoxib (CCX, Mw = 381.37 g/mol) was purchased from AK Scientific, Inc. (Union City, 
CA, USA). Celecoxib (Fig 15), 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] is 
a NSAID selectively inhibiting COX-2.  Celecoxib is used to treat symptoms of osteoarthritis 
and rheumatoid arthritis (Paulson et al., 2001). Celecoxib is a weak acid with a pKa of 11.1 and 
is classified as BCS II drug due to its poor water solubility (≅5 μg/ml). The melting temperature 
of celecoxib is 158°C. Crystalline Celecoxib form long, needle like crystals. (Chawla, Gupta, 








Soluplus® was purchased from BASF SE (Ludwigshafen, Germany). Soluplus is a graft 
copolymer consisting of a polyethylene glycol (PEG) 6000 backbone with 
polyvinylcaprolactam  (PVCL) and polyvinyl acetate (PVAc) side chains. Soluplus is an 
amphiphilic polymer, where PEG functions as hydrophilic part and the PVCL/PVAc side 
chains function as lipophilic part. This allows Soluplus to form micelles in aqueous solutions 
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above the critical micelle concentration (CMC) of 7.6 mg/ml (Ali et al., 2015). Soluplus consists 
of white to yellowish free-flowing granules and has a Mw of 118 000 g/mol.Soluplus was 
developed for use in solid dispersions and shows good extrudability and flowability. (Tsinman, 
Tsinman, & Shaukat, 2015). Soluplus has a reported 𝑇𝑔 of approximately 70 °C (Caron et al., 
2013).  
 
Figure 16. Soluplus  
5 Methods 
 
5.1 Hot Melt Extrusion  
 
The extrusions were conducted using a lab-scale twin screw extruder with two co-rotating 
conical mixing screws (DSM Xplore Micro Compounder) (Fig 17). 
The API-polymer mixtures were manually mixed using a mortar and pestle in weight to weight 
(w/w) ratios of 10:90, 30:70 and 50:50 to investigate the influence of drug-polymer ratio in the 
extrudates. The API-polymer mixtures were extruded at 120 °C with a screw speed of 50 rounds 
per minute (RPM). The three heating zones of the extruder were set to 120 °C and allowed to 
equilibrate. Approximately 5-10g of the API-polymer mixture was fed manually through a 
hopper. The mixtures were extruded using different circulation times, in which the mixtures 
were melted and recirculated inside the extruder. The mixtures were extruded either without 
recirculation as continuous manufacturing or as a batch with a 5-minute recirculation time to 
investigate how the time of exposure to the heat in the molten state affects the extrudates. 
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The extrudates were manually collected and cooled at ambient conditions. The collected 
extrudates were grinded using a mortar and pestle for further analysis. Some strands were also 
collected for a stability study.  
 
 
Figure 17 Laboratory scale extruder with a co-rotating twin-screw setup  (DSM Xplore Micro Compounder) 
5.2 Stability study 
 
Strands and grinded extrudates produced using HME were stored at a 95% relative humidity 
at 40 °C. The extrudates were analysed using Raman spectroscopy and PLM at d0, d30, d60. 
The samples are presented in Table 3. 
 
Table 3 List of samples chosen for stability studies.  
API Polymer %API %Polymer Method Recirculation time (min) 
NAP Soluplus 10 90 HME 0 
NAP Soluplus 10 90 HME 5 
NAP Soluplus 30 70 HME 0 
NAP Soluplus 30 70 HME 5 
NAP Soluplus 50 50 HME 0 
NAP Soluplus 50 50 HME 5 
CCX Soluplus 10 90 HME 0 
CCX Soluplus 10 90 HME 5 
CCX Soluplus 30 70 HME 0 
CCX Soluplus 30 70 HME 5 
CCX Soluplus 50 50 HME 0 
CCX Soluplus 50 50 HME 5 
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5.3 Vacuum compression moulding 
 
API-polymer disks for rheological studies and DSC were prepared using VCM. The disks were 
prepared using a MeltPrep® tool (MeltPrep GmbH, Austria). The samples were prepared at 
120 °C with a dwell time of 15 minutes to mimic the HME process. Some samples were also 
prepared using higher temperatures and analysed using PLM and Raman to determine the effect 
of temperature on the API-polymer disks.  
For the rheological studies samples of grinded extrudates were prepared into suitable 25mm 
disks using VCM. The process temperature was set to 100 °C. The temperature was chosen as 
lower than the extrusion temperature so as not to affect the samples further after the extrusion 
process. 
 
5.4 Rheological analysis 
 
The rheological analyses were conducted using an AR-G2 rotational rheometer (TA 
Instruments) (Fig 18) with a heating test chamber. 25-mm parallel-plate geometries were 
selected for the analyses based on the viscosity of the samples. The linear viscoelastic region 
(LVR) was determined for Soluplus using s a strain sweep at the strain amplitude range of 
0.015% to 15% at 120°C at a constant angular frequency of 10 Hz.  
SAOS frequency sweeps were run in the LVR at 120°C at a constant strain amplitude γ = 0.5% 
and decreasing angular frequency from 100 to 0.01 Hz. The experiments were ran using 25mm 
disks prepared using VCM and weighing approximately 500mg. A gap of 0.75mm between the 
parallel plates was used for all sample measurements. 
Supporting temperature sweep measurements in SAOS were run at constant strain amplitude 
γ = 0.5% (within the LVR) and constant angular frequency ω= 1 Hz.  The measurements were 
run from 100°C to 180°C. The complex viscosity was used to assess the melt processability of 
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Figure 18 AR-2 Rheometer (Trios) 
5.5 Thermogravimetric analysis 
 
Thermogravimetric analysis (TGA) was performed using a Discovery TGA (TA Instruments, 
New Castle, DE, USA) controlled by TRIOS software (TA Instruments, New Castle, DE, 
USA). Samples were analysed in flame-cleansed open platinum pans. TGA was used to 
determine degradation temperatures of NAP and CCX to ensure that no significant degradation 
occurred at used process temperatures. The samples of pure crystalline API were heated up to 
300°C.  
 
5.6 Differential Scanning Calorimetry 
 
Thermal analyses were performed using a modulated differential scanning calorimetry (MDSC, 
Q100, TA Instrument, Elstree, UK). Modulated temperature DSC was used to determine the 𝑇𝑔 
of the samples prepared by HME and VCM. Physical mixtures of the same ratios were also 
used as a reference. 2-11 mg of sample were packed into an aluminium pan with a non-hermetic 
lid. For HME the extrudates were ground using a mortar and pestle before sampling. VCM 
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samples were prepared using the pan-sized 5mm disk tool on the MeltPrep weighing 
approximately 10mg. Physical mixtures were manually mixed.  
The inflection Tg’s were determined from the reversing heat flow in the modulated DSC to 
avoid interference from enthalpic relaxation. This was done by taking the derivative and 
selecting the minimum value. 
The samples were heated to 100° (Ramp 1) and kept isothermal for 2 min to get rid of moisture 
and reduce the effect of enthalpic relaxation. The samples were cooled down to -50°C before 
heating up to 170°C at 5°C/min (Ramp 2). After Ramp 2 the samples were cooled back down 
to -50 and heated up to 170°C for a second time (Ramp 3) to see if the 𝑇𝑔 would be affected of 
heating above the Tm  of the API. The DSC program is summarized in Table 4.  
Table 4 Modulated DSC program for 𝑇𝑔 determination 
Step Description 
1 Equilibrate -50,00 °C 
2 Modulate Temperature Amplitude 0,5310 °C , Period 40,0 s 
3 Ramp 5,00 °C/min to 100,00 °C 
4 Isothermal 2,00 min 
5 Equilibrate -50,00 °C 
6 Modulate Temperature Amplitude 0,5310 °C , Period 40,0 s 
7 Ramp 5,00 °C/min to 170,00 °C 
8 Equilibrate -50,00 °C 
9 Modulate Temperature Amplitude 0,5310 °C , Period 40,0 s 
10 Ramp 5,00 °C/min to 170,00 °C 
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5.6.1 Solubility determination 
 
200mg of high drug load drug-polymer mixtures were manually mixed using a mortar and 
pestle with low force (Table 5). The melting point depression was measured using DSC. 
Approximately 2 mg of powder were packed in aluminium pans. The lid was pinholed for 
moisture to escape. The samples were heated above the melting point up to 170°C by 1°C/min. 
The onset of melting for each sample was determined using Trios software and was used to 
calculate solubility of the APIs in polymer. The results were extrapolated to room temperature 
using the Flory-Huggins equation described earlier in this thesis. The volume fractions of the 
drug and polymer were calculated by dividing the weight fractions by the amorphous densities 
of the materials. For NAP the crystalline density was used instead due to the difficulty of 
producing a amorphous sample of pure NAP.  
Table 5 API:polymer fractions used for the solubility determination of NAP and CCX in Soluplus 
NAP Soluplus  CCX Soluplus 
75 25  70 30 
80 20  75 25 
85 15  80 20 
90 10  85 15 
100 0  100 0 
 
The sample preparation for solubility determination of CCX in Soluplus was performed by Ana 
Calduch Arques. 
 
5.7 Stability study 
 
Strands and grinded extrudates were stored at a 95% relative humidity at 40 °C. The extrudates 
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5.8 Raman spectroscopy 
 
Raman spectroscopy was performed using a Kaiser RXN1 Microprobe (Kaiser Optical 
Systems, Ann Arbor, MI, USA) equipped with a PhaT-probe (Kaiser Optical Systems). The 
laser wavelength was 785 nm and the Raman shifts were measured from 150 to 1900 cm-1 with 
each spectrum comprising of 5801 data points. The exposure time was 5 seconds with 1 
accumulation. Triplicates of each sample were gathered from different parts of the samples. 
The optimal region for predicting amorphisity of the samples were selected and confirmed by 
literature. For CCX the region from 770 to 840 cm−1 was selected. The amorphisity can be 
observed as a peak shift from 810 cm−1  for crystalline CCX to 798 cm−1 for the amorphous 
CCX. The 798 cm−1 peak seems to merge with a peak observed at 794 cm−1. This shift has also 
been observed by Edinger et al. (Edinger et al., 2018) The shift is explained as a change in the 
intermolecular structure surrounding the phenyl ring in CCX. For NAP a region from 1610 to 
1650 cm−1   was selected. The amorphization of NAP causes a minor peak shift from 1630 for 
crystalline NAP to 1634 cm−1  for amorphous NAP. This shift is due to the change in the 
intermolecular structure surrounding the aromatic ring structure of NAP. This shift has also 
been presented by  Allesø et al. (Allesø et al., 2009).  
The obtained Raman spectra were pre-processed using Standard normal variate correction 
(SNV) and trends were visualised using Principal component analysis (PCA). 
 
5.9 Polarized light microscopy 
 
Polarized light microscopy (PLM) was performed using a Leica DM LM microscope (Leica 
Microsystems GmbH, Wetzlar, Germany) equipped with a 40× objective. Microscope images 
were obtained using an Evolution MP camera (Media Cybernetics, Rockville, MD, USA) 
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6 Results 
 
6.1 Stability of raw materials 
 
Before starting the HME process and the rheological studies, stability of the raw materials at 
the process temperatures had to be ensured. The degradation temperatures for NAP, CCX and 
Soluplus were established by thermogravimetric analysis.  Results are shown in Figure 19. No 
significant weight loss could be observed at the chosen extrusion temperatures of 120-130°C.  
The initial weight loss of Soluplus is due to water evaporating from the sample. NAP starts 
degrading at temperatures over 150°C. CCX an Soluplus appear to be stable at temperatures 
exceeding 200ºC. Therefore, the chosen extrusion temperature was regarded as safe. 
 
Figure 19 Thermogravimetric analysis diagram of CCX(blue), NAP(green) and Soluplus(red) showing weight loss 
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6.2 Solubility determination 
 
Using the Flory-Huggins theory and melting point depression in oversaturated API-polymer 
samples in the DSC, an estimate of the solubility of API in Soluplus for both NAP and CCX 
were determined. The fraction of drug that will fully dissolve in Soluplus at a given temperature 
is presented in Figure 20& Figure 21. At the chosen process temperature for HME and VCM 
at 120°C an estimated 61% (53-67%, 95% confidence) of NAP will be soluble in Soluplus. In 
other words in a 61:39 NAP:SP ratio all NAP should be soluble and able to disperse in the 
polymer mixture. The corresponding amount of soluble CCX at 120°C is 32% (13-45%, 95% 
confidence).  
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Figure 21 Solubility estimation of CCX in Soluplus with 95% confidence intervals. 
 
NAP shows a high solubility in Soluplus and show good extrusion characteristics at the chosen 
process temperatures. The extrapolation of solubility would indicate that even at room 
temperature approximately a 20% NAP content would be fully soluble in Soluplus. The low 
solubility of CCX, closing at a 0-5% estimated solubility at room temperature indicates that 
Soluplus is not an ideal polymer for producing ASD’s with CCX, especially at higher drug 
contents. 
 
6.3 Preparation of solid dispersions 
 
6.3.1 Hot-melt extrusion 
 
The chosen API-polymer mixtures showed good extrudability at the chosen process temperature 
of 120ºC and the screw speed of 50 RPM, allowing for both continuous extrusion with 
immediate collection of the extrudates, as well as extrusion prepared by batch processing with 
a 5-minute recirculation within the extruder, before opening of the extrusion valve. However 
the 50:50 NAP:Soluplus extrudates exhibited low viscosity and were sticky at collection. This 
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50:50 NAP:Soluplus, change of process parameters (lower temperature or screw speed) or 
improved collection of the extrudates from the die, to prevent lumping of the sample, is 
recommended.  
Approximately 5-10 grams powder mixture was used for each batch produced. The powder was 
manually fed into the extruder until the chamber was considered full and a stable melt pressure 
was obtained. The recirculation time was recorded from the end of feeding to start of extrusion, 
thus the time inside the extruder is more than 5 minutes for the batch manufactured extrudates. 
During some of the extrusions the chamber reached a maximum melt pressure of 5000N, 
activating a safety setting and shutting off the engine. In this case the motor was restarted and 
some of the sample allowed to exit the extruder. All parameters of the extruder were recorded 
and stored including melt pressure and temperature. 
For the batch produced, 5-minute recirculated samples the melt pressure quickly dropped after 
opening the valve and forming the extruded strand from the die. This led to a slowing of the 
extrusion after the initial start. The first and last part of the extrudates were discarded and the 
rest were chosen for further analysis. 
 Upon exiting the die, the extrudates ranged from clear to opaque (Fig 22&23). The extrudates 
containing CCX were stiff and brittle. Extrudates containing NAP were more flexible at higher 
drug content, but still exhibited brittleness when force was applied.  
The produced extrudates of NAP in Soluplus (Fig 22) decreased in thickness with increased 
drug content even though the same die was used for all samples. This was probably due to lower 
viscosity of the melt. The extrudates with 10% and 30% NAP content were clear, while the 
50% NAP exhibited cloudiness possibly indicating residual crystals in the solid dispersion. 
 The corresponding extrudates with CCX in Soluplus showed a more opaque, cloudy 
appearance (Fig 23). The extrudates were also thicker and having a higher viscosity in the 
extrusion process compared with extrudates containing NAP. This would indicate that CCX 
does not have a plasticizing effect of the same magnitude as NAP. The opaque nature of the 
extrudates can indicate crystallinity but may also be due to characteristics of the raw materials. 
This can be correlated with the poor solubility of CCX in Soluplus shown by the Flory-Huggins 
model. It is possible the opaque nature is due to undissolved CCX in the extrudates.  
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Figure 22 Extrudates of NAP in Soluplus. Fraction of NAP and the recirculation time in the extruder given for each 
picture  
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Figure 23 Extrudates of CCX in Soluplus. Fraction of CCX and the recirculation time in the extruder given for each 
picture 
 
Due to the high viscosity and opaque appearance of the extrudates containing CCX, a test 
extrusion with 50:50 CCX:Soluplus was done at 130°C with a 5 minute recirculation. The 
elevated temperature together with the recirculation time in the extruder seemed to give the 
extrudate a clearer appearance (Fig 24). The extrudate was included in further analytical studies 
to see if the amount of amorphous API had increased by elevated temperature. 
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Figure 24 Comparison of exrudates of 50:50 CCX:Soluplus at different temperatures. 120ºC with no recirculation 
(left) and 130ºC with 5 minute recirculation in the extruder 
All the extrusions were conducted well under the melting temperature of the API’s. NAP has a 
reported melting point of 153ºC and CCX 158ºC. 
 
6.3.2 Vacuum compression moulding 
 
To mimic the extrusion process corresponding API-polymer samples were prepared using 
VCM. API-polymer disks were prepared from physical mixtures using the MeltPrep®-tool at 
elevated pressure and temperature. The goal was to obtain homogenous samples of solid 
dispersions, optimal for rheological analysis and DSC that could be used for screening mixtures 
before commencing large-scale extrusions. The temperature was chosen as 120°C, same as the 
process temperature in the extruder. Some test samples were also prepared at elevated 
temperatures of 130°C and 170°C.  
Due to the lack of mixing and shear in the VCM the disks did not appear homogenous. The 
disks showed drug rich deposits when visually inspecting them, while other parts were clear. 
Both for CCX and NAP 50% disks were flaky and white, powdery on the surface, indicating 
high crystal content.   
VCM was also used to produce disks of the extrudates from the melt-extrusion. The grinded 
extrudates were heated up to 100°C at elevated pressure in order to produce 25mm disks similar 
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to the disks prepared from the raw materials. The disks prepared from extrudates had a much 
clearer appearance compared with the disks from raw materials (Fig 25&26).  
 
Figure 25 VCM disks of CCX:Soluplus. Top row is prepared from physical mixture(PM) .Second row is extruded 
without recirculation at 120°C and third row is extruded with 5 minute recirculation time. Samples prepared using 
MeltPrep®   
 
   
Figure 26 VCM disks of NAP:Soluplus. Prepared of grinded extrudates using the MeltPrep at 100°C. The extrudates 
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For a rheological temperature sweep measurement samples from physical mixtures were 
prepared at 100°C for 15 minutes using the VCM. All the samples were white non-transparent 
(Fig 27&28). A sample of 50% CCX would not melt together at 100°C and was left out of the 
temperature sweep measurements. The disks containing CCX seemed to have a more crystalline 
structure compared to disks containing NAP when visually inspecting them.  
 
Figure 27 VCM-disks of NAP:Soluplus 10-30-50% API content. Prepared at 100ºC from physical mixtures for 
temperature sweep analysis 
 
Figure 28 VCM-disks of CCX:Soluplus. 10% CCX (left) and 30% CCX (right). Prepared at 100ºC from physical 
mixtures for temperature sweep analysis 
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6.4 Raman spectroscopy 
 
Raman spectroscopy was evaluated as a technique for  determining amorphicity of the samples. 
Due to the speed of measurements, Raman spectroscopy could potentially be used as a PAT 
tool for HME. 
 
6.4.1 Naproxen  
 
Naproxen as a GFA class I compound has a tendency to rapidly recrystallize from its amorphous 
state. Therefore naproxen is very difficult to make amorphous by itself. The polymer matrix of 
Soluplus however “locks” NAP in its amorphous state due the the high glass-transition 
temperature of Soluplus. 
In Figure 29 a comparison of the crystalline and amorphous Raman shift of NAP can be seen. 
The amorphisation of NAP causes a minor peak shift from 1630 for crystalline NAP to 1634 
cm−1  for amorphous NAP. 
  
Figure 29 Crystalline NAP (green) and amorphous NAP in Soluplus (blue). 
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The chosen region for NAP was 1610 to 1650 cm−1  and the obtained spectra were preprocessed 
using SNV. The results are presented in Figure 30. Here, a comparison between the solid 
dispersions prepared by HME and VCM (MeltPrep®, MP) were compared. Spectra of 
corresponding physical powder mixtures were also measured.  
 
Figure 30 SNV corrected Raman spectra of NAP:Soluplus solid dispersions. Coloured according to manufacturing 
method. HME (green) MeltPrep (blue) and physical mixtures for reference (red) 
 
By using the statistical method of PCA of the interesting region in the spectra some further data 
can be obtained. By comparing the SNV processed spectra for the chosen Raman region of 
1610-1650 cm−1 for NAP, with the loadings plot for PCA-1 (Fig 31) a negative correlation 
between the crystallinity of the sample and the PC-1 plot can be observed. By visualizing the 
data in a scores plot plotting PC-1 against PC-2 the observed data points show a tendency 
towards increased amorphous content along the x-axis (PC-1), with crystalline physical 
mixtures giving a negative result (Fig 32).  The PC-2 is not conclusive in this context and will 
not be analysed further. PCA indicate that there is a difference between the solid dispersions 
prepared by HME compared to VCM, especially at higher drug loads. However, it appears that 
the use of high temperature VCM can yield similar results to extrudates prepared using HME.  
Further experiments with varying process parameters are required to better assess the suitability 
of VCM as a screening tool. 
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Figure 31 Loadings plot of the first component (PC-1) 60,4% explained variance 
 
When comparing HME and VCM using PCA, some of the samples prepared by VCM are more 
towards the crystalline reference. Especially at 50% NAP content the HME seems to have more 
amorphous content compared to VCM (Fig 32-34). Due to the partial overlapping of the Raman 
shifts and low signal to noise ratio a quantitative estimation is difficult to make. In thee PLM 
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Figure 32 PCA of NAP:Soluplus. Coloured according to preperative method. HME (green) VCM (blue) and 
physical mixtures as referene (red) 
 
Figure 33 PCA of NAP:Soluplus. Coloured according to process temperature. 120ºC (blue) 130ºC (red) and 
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Figure 34 PCA of NAP:Soluplus. Coloured according to naproxen content. 10% (dark blue) 25% (red) 30% 




For celecoxib the chosen Raman shift can be observed as a peak shift from crystalline CCX at 
810 cm−1  to amorphous CCX at 798 cm−1 for the amorphous CCX. The 798 cm−1 peak merges 
with a peak observed at 794 cm−1 (Fig 35). 
 
 
Figure 35 SNV spectra of 100% crystalline (red) and 100% amorphous (yellow) CCX. 
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When comparing the spectra of the different preparative methods (Fig 36&37), the solid 
dispersions prepared by VCM show a higher crystalline content while the solid dispersions 
prepared by HME seem to be mainly amorphous. Both the 30% and 50% CCX content VCM 
disks show crystallinity prepared at 120°C. 50% CCX was also prepared using VCM above the 
melting point of CCX at 170°C for 15 minutes. The results indicate that the elevated 
temperature manages to amorphise the CCX in the VCM tool.  
 
Figure 36 SNV corrected Raman spectra of CCX:Soluplus solid dispersions. Coloured according to manufacturing 
method. HME (green) MeltPrep (blue) and physical mixtures for reference (red) 
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Figure 37 SNV corrected Raman spectra of CCX:Soluplus solid dispersions. Coloured according to process 
temperature. 120°C(yellow) 130°C(green) 170°C (blue) and physical mixtures for reference (red) 
By comparing the SNV processed spectra for the chosen Raman region of 760-840 cm−1 with 
the loadings plot for PCA-1 (Fig 38), a positive correlation between the crystallinity of the 
samples and the PC-1 plot can be observed. By visualizing the data in a scores plot plotting PC-
1 against PC-2 the observed data points show a tendency towards increased crystalline content 
along the x-axis (PC-1), with crystalline physical mixtures giving a positive result (Fig 39).  
The PC-2 is not conclusive in this context and will not be analysed further.  
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Figure 38 Loadings plot of the first component (PC-1) 57,3% explained variance 
 
 
The PCA further visualises the Raman data. As seen in Figure 39 all the samples prepared by 
HME are aligned on the negative side of PC-1 indicating amorphous CCX. The physical 
mixtures confirm the positive correlation between crystallinity as they contain crystalline CCX.  
Some samples prepared by VCM also align towards the crystalline side of PC-1. The samples 
containing 30% and 50% CCX prepared at 120 or 130°C seem to be crystalline while the 50% 
CCX prepared with VCM at 170°C for 15 minutes seem to be mainly amorphous (Fig 40 & 
41). The samples prepared at 170°C can be observed in the top left corner with numbers 57-59. 
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Figure 39 PCA of CCX:Soluplus. Coloured according to manufacturing method. HME (green) MeltPrep (blue) and 
physical mixtures for reference (red) 
 
Figure 40 PCA of CCX:Soluplus. Coloured according to CCX content. 10% (blue) 25% (red) 30% (yellow) 50% 
(teal). 100% crystalline CCX (purple) and Soluplus (green) for reference  
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Figure 41 PCA of CCX:Soluplus. Coloured according to process temperature. 120°C (blue) 130°C (red) and 
170°C (yellow). Physical mixtures as reference, na (green) 
 
 
6.5 Rheological properties 
 
Small amplitude oscillatory shear (SAOS) rheology was used to compare solid dispersions 
prepared by HME and VCM. The effect of recirculation time in the extruder was also evaluated.  
Rheology was used to assess the plasticizing effect of the model API’s in Soluplus, as well as 
to investigate the solubility of API in Soluplus. The extent of shear thinning of the API-polymer 
melt in the extruder due to shear forces from the rotating screws was investigated but no 
correlation was observed between shear thinning and API content. The measured force within 
the extruder was fluctuating and no conclusive data was obtained. However, the shear forces 
within the extruder can be expected to contribute to the forming of ASD’s in the extruder due 
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6.5.1 Determination of linear viscoelastic region 
 
The LVR was determined using a strain sweep with increasing oscillation strain on the sample. 
The LVR for Soluplus range from 0-1.44% oscillation strain (Fig 42) where the polymer 
structure remains unaltered. When exceeding the LVR the melt structure is destroyed as the 
molecule chains start to reorganize. A strain of 0.5% was selected for further rheological 
analyses.   
 
Figure 42 Strain sweep of Soluplus. The LVR can be observed from 0-1.44% where the polymer structure remains 
unaltered. When exceeding the LVR the melt structure is destroyed as the molecule chains start to reorganize.  
SAOS frequency sweeps were run in the LVR at 120°C at a constant strain amplitude γ = 0.5% 
and decreasing angular frequency from 100 to 0.01 Hz. The complex viscosity of the samples 




The complex viscosity (ƞ*) between the different preparative methods varied considerably 
especially at the higher drug-loads (Fig 43). The lack of mixing and shear forces in VCM leads 
to less amorphization and higher crystal content of drug in the mixture, which can be observed 
as an increased melt viscosity. The difference is especially evident at higher drug loads where 
Soluplus StrainSweep
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the mixing is critical for forming an ASD. The results also indicate that the extrusion process 
with a 5-minute recirculation shows lower complex viscosity compared with the extruded 
samples without recirculation indicating further amorphisation during recirculation within the 
extruder. However, both extrusion samples show lower viscosity compared to the VCM 
samples at 50% drug load. The results also show that the dissolved NAP can act as a plasticizer 
lowering the melt viscosity of the API-polymer mixture.  
The results show the effect of the mixing and shear of the screws inside the extruder. Also at 
higher drug loads by increasing the dwell time inside the extruder by 5 minutes with continuous 
mixing it seems to further dissolve and disperse the API inside the polymer matrix. 
 
Figure 43 Complex viscosity of NAP-Soluplus solid dispersions. API content 10% (blue) 30% (green) 50% (red). Preparative 
methods: HME without recirculation (), HME with 5 min recirculation time () and VCM (). Soluplus (yellow) for reference 
 
The PLM pictures of the rheological disks prior to the experiments support the findings (Fig 
44). It seems at 10% the crystal content is low in all the samples and even VCM alone manages 
to turn the majority of NAP amorphous. At 30% a much larger difference between the different 
preparative methods can be seen, as the VCM sample with only MeltPrep® show a much higher 
crystallinity compared to the extrudates. At 50% NAP content plenty of crystalline NAP can be 
observed in all three samples. However, the rheological data would indicate that the extruded 
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with the MeltPrep® sample. The rheological data also show an increased importance of 
recirculation time in the extruder allowing for further melting and amorphisation of NAP.  
 
Figure 44 PLM pictures of 25mm disks prepared with MeltPrep® (MP). Left column is from grinded extrudates from 
HME without recirculation, middle column with 5-minute recirculation within the extruder and right column disks 
from physical mixtures. Amount of NAP in Soluplus given as percent. 
Due to lack of experience in the use of the PLM, the settings between the pictures as well as 
the magnification of the samples might vary. The lack of scaling for each picture also makes 
the results shown less quantitative and more speculative in nature. However, it is apparent that 
some assumptions can be made on basis of the PLM data. To further support the rheological 
results and PLM data, Raman spectroscopy was used. The Raman data as presented in chapter 
6.4.1. suggest that all HME samples and most VCM samples are amorphous. Due to the close 
proximity of the Raman shifts together with slight overlapping it is unsure how reliable the data 
is. PLM clearly show crystals on all samples containing 50% NAP. Due to the contradicting 
nature repeating of samples should be conducted and the crystallinity re-evaluated. What clearly 
can be concluded is that drug content ant preparative method have an effect on the viscosity of 
the drug-polymer melt. 
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6.5.3 Celecoxib  
 
For samples containing CCX the complex viscosity of the prepared VCM disks were higher 
compared to the disks containing NAP. Some of the samples showed higher viscosity compared 
with pure Soluplus (Fig 45). This indicates that CCX does not have a significant plasticising 
effect on the melt in contrast to samples containing NAP, which showed a decrease in viscosity 
with increased drug load even at drug loads of 50%. The rheological data show a very big 
difference between the preparative methods of HME and VCM at 50% drug content. This would 
indicate that the VCM sample contains a much higher crystal content compared to the extruded 
samples and thus increasing the melt viscosity.  
 
 
Figure 45 Complex viscosity of CCX-Soluplus solid dispersions. API content 10% (blue) 30% (green) 50% (red). 
Preparative methods: HME without recirculation (), HME with 5 min recirculation time () and VCM (). Soluplus (yellow) 
for reference 
 
For CCX a significant difference of crystallinity observed using PLM could be seen already at 
10% CCX content (Fig 46). The disk prepared from physical mixture using only MeltPrep® 
showed plenty of crystals while the continuously extruded sample showed a few crystals and 
the extruded sample with recirculation time within the extruder showed even less or possibly 
no crystals in the sample disk. The trend continues throughout all of the samples, where the 
samples prepared by VCM show highest crystallinity, then the non-recirculated extrudates and 
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Figure 46 PLM pictures of 25mm disks prepared with MeltPrep® (MP). Left column is from grinded extrudates from 
HME without recirculation, middle column with 5-minute recirculation within the extruder and right column disks 
from physical mixtures. Amount of CCX in Soluplus given as percent. 
 
The Raman data for CCX presented in chapter 6.4.2. supports the PLM data where both 30% 
and 50% CCX solid dispersions prepared by VCM show significantly higher crystal content 
when comparing to the extruded samples. When comparing with the solubility estimation of 
CCX in Soluplus done using the Flory-Huggins model it is possible that the disks remain highly 
crystalline in the rheological analysis thus increasing the viscosity of the sample. The 50% 
sample prepared by VCM show the highest viscosity throughout and it is significantly higher 
than that of Soluplus alone. 
6.5.4 Temperature sweep 
 
Temperature sweeps of disks prepared using VCM at 100°C were performed from 100°C to 
180°C to see the effect of temperature on the melt viscosity of the API-polymer mixtures. 
However the data cannot be relied heavily on due to the runny nature of Soluplus at high 
temperatures preventing the sample from staying between the geometries and running along the 
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sides of the lower geometry. This can be observed in the raw data included in the appendix 
where the storage modulus shows heavy fluctuation. A fast lowering of the viscosity of Soluplus 
after 150°C can be observed. (Fig 47) For samples containing NAP the inflection happens 





Figure 47 Temperature sweep of NAP:Soluplus mixtures prepared on MeltPrep® at 100°C 
For CCX the complex viscosity remained higher than the complex viscosity of Soluplus alone (Fig 48). 
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6.6 DSC 
 
Modulated temperature DSC was used to determine the 𝑇𝑔 of the samples prepared by HME 
and VCM. The results are presented in Table 6. 
Table 6 Tg (inflection) of prepared solid dispersions using reversing heat flow on the DSC. API fraction in 
Soluplus given as %. Preparative methods Hot-melt extrusion (HME) or VCM using MeltPrep (MP). Phyiscal 
mixtures and Soluplus standard as reference. 
  Tg inflection   Tg inflection 
  Ramp 2 Ramp 3   Ramp 2 Ramp 3 
Soluplus std 74,2 78 Soluplus std 74,2 78 
HME NAP 10% 0min 66,1 62 HME CCX 10% 0min 77,6 79,3 
HME NAP 10% 5min 66,3 67,5 HME CCX 10% 5min 71,9 79,7 
HME NAP 30% 0min 54,4 51,8 HME CCX 30% 0min 72,2 79,1 
HME NAP 30% 5min 52,6 46,5 HME CCX 30% 5min 87,1 77,5 
HME NAP 50% 0min 44,1 37,9 HME CCX 50% 0min 75,4 74,3 
HME NAP 50% 5min 37,8 36,8 HME CCX 50% 5min 75,5 81 
MP NAP 10%  50,9 60 MP CCX 10%  75,2 76 
MP NAP 30% 39,1 43,2 MP CCX 30% 70,6 76,1 
MP NAP 50% 34,4 32,7 
Physical mixture CCX 
10% 74,5 84,5 
Physical mixture NAP 
10% 74,6 70,1 
Physical mixture CCX 
30% 75,1 70,4 
Physical mixture NAP 
30% 112,7 55 
Physical mixture CCX 
50% 108,1 59,7 
Physical mixture NAP 
50% 82,3 46,5       
 
With increased NAP content in the samples the 𝑇𝑔 𝑖𝑛𝑓𝑙𝑒𝑐𝑡𝑖𝑜𝑛  dropped. This would further 
confirm that NAP acts as a plasticizer within the mixture lowering the glass transition 
temperature and the melt viscosity. This was also observed in the behaviour of the drug-polymer 
melt during extrusion. CCX does not show the same trend in declining  𝑇𝑔 𝑖𝑛𝑓𝑙𝑒𝑐𝑡𝑖𝑜𝑛 .The 
𝑇𝑔 𝑖𝑛𝑓𝑙𝑒𝑐𝑡𝑖𝑜𝑛 remains similar to that of pure Soluplus. It is worth noting that due to the broad 
glass transition temperature of Soluplus, the determination of Tg was not considered very 
accurate. As seen in Figure 49 the glass transition temperature can be seen as a broad slope 
ranging for a broad temperature spectrum with local inflection points. It could be suggested that 
the Tg should be given as a range instead of a specific value for API-polymer mixtures 
containing Soluplus. However, in this thesis the determination of glass transition temperature 
has been chosen as the inflection point of the transition with the steepest curve as seen in Figure 
49. This was done by derivatising the observed DSC curve and choosing the signal minimum 
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in the range of glass-transition. The results are summarised in Table 6 and the corresponding 
curves can be found in the Appendix  
 
 
Figure 49 50 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME  CCX:Soluplus 30:70 5min recirculation   
For samples containing CCX the 𝑇𝑔 is partially merged with a broad endotherm reaction 
occurring after the 𝑇𝑔 further complicating the estimation of the 𝑇𝑔 . This was thought to be the 






Page 65 of 132 
6.7 Influence of storage 
 
Raman and PLM were used to determine the stability of the solid dispersions prepared by HME. 
The samples were stored at 95% relative humidity at a temperature of 40°C and measured at 
day 0, day 30 and day 60.  
6.7.1 Naproxen  
 
For NAP all samples seemed to be mainly amorphous at day 0 right after the extrusion. The 
Raman data indicates that already at day 30 of storage, the extrudates containing 50% NAP 
have turned crystalline. The shift left towards crystalline state can be observed in the SNV 
enhanced Raman spectra (Fig 51&52). The crystalline peak for NAP can be observed at 1630 
cm−1. This occurred for both the non-recirculated one as well as the 5-minute recirculated 
sample. The spectra indicate that the rest of the extrudates containing NAP have remained 
mainly amorphous. To further analyse the Raman data PCA was used.  By using PCA, a positive 
correlation between PC-2 and crystallinity of NAP can be observed (Fig 53). The PCA results 
support the spectral data in grouping 50% NAP samples measured at day 30 and day 60 to the 
right giving them a positive value while all the other samples group up on the negative side, 
indicating that NAP is still in its amorphous state within the polymer matrix (Fig 54).  
 
 
Figure 51 SNV corrected Raman spectra of NAP:Soluplus solid dispersions prepared by HME and stored at 95% 
relative humidity at 40ºC. Coloured by storage day. Day 0 (green), day 30 ( blue) and day 60 (red). 
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Figure 52 SNV corrected Raman spectra of NAP:Soluplus solid dispersions prepared by HME and stored at 95% 
relative humidity at 40ºC. Coloured by NAP content. 10% (green) 30%(blue) and 50%(red) 
 
Figure 53 Loadings plot of the second component (PC-2) 24,8% explained variance 
 
 
Figure 54 PCA of NAP:Soluplus extrudates during storage. Coloured by drug content (left) and storage time 
(right) 
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The results are to some extent supported by the polarized light microscopy. For 10% NAP no 
crystals are observed at day 0. However, at day 30 and day 60 some possible crystals can be 
observed (Fig 55) Due to the nature of the extrudates it is difficult to determine if this is only 
on the surface of the strands that are in direct contact with the moisture in the desiccator. The 
Raman still indicates that the 10% NAP samples are mainly amorphous. It can also be discussed 
if the results can be due to sampling error. Raman uses a narrow laser light that only samples a 
very small portion of the sample, while PLM can be moved over large areas using visual 
examination. The signal to noise ratio on the Raman data was also low and had to be heavily 
pre-processed using SNV to obtain the spectra. 
 
Figure 55 PLM of 10% NAP prepared by HME without recirculation (left) and with a 5-minute recirculation (right) 
during storage.  
For 30% NAP extrudates only a few possible crystals were observed using PLM (Fig 56). The 
extrudates are also aligned more towards the negative side in the PCA compared to 10% 
indicating that it is possible the 30% NAP samples were more stable than the 10% and 
maintained their amorphous state. 
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Figure 56 PLM of 30% NAP prepared by HME without recirculation (left) and with a 5-minute recirculation (right) 
during storage. 
 
The 50% NAP samples show thick, white crystalline structure from day 30 and day 60 for both 
strands extruded continuously as well as with 5-minute recirculation in the extruder (Fig 57). 
At day 0 some crystals could be observed in both samples but the samples appeared to be mainly 
amorphous. At d30 and d60 the PLM picture is take from the edge of the sample in order to get 
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enough light to get a picture of the thick crystalline structure supporting the Raman data 
indicating crystallinity for 50% NAP after 30 days of storage. 
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6.7.2 Celecoxib 
 
For the extrudates containing CCX the Raman spectra indicates that all samples are in the 




Figure 58 SNV corrected Raman spectra of CCX:Soluplus extrudates during storage 
 
When comparing with the PLM pictures however, some crystals can be observed. The 10% 
CCX samples only show a few crystals possibly only on the surface of the extruded strands 
(Fig 59). It is also possible that the crystals are residual dust from grinded extrudates or some 
other impurities on top of the samples. 
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Figure 59 PLM of 10% CCX prepared by HME without recirculation (left) and with a 5-minute recirculation (right) 
during storage. 
The 30% CCX samples indicate more crystals when visually comparing the PLM pictures with 
the 10% CCX (Fig 60). At day 0 the recirculated sample did not show any crystals while the 
continuously manufactured (0min) extrudate showed a few crystals. At d 30 more crystals could 
be observed on the 0min sample. The recirculated sample also showed some that appeared to 
be crystals within the extrudate. At d60 no visual increase of crystals could not be confirmed. 
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Figure 60 PLM of 30% CCX prepared by HME without recirculation (left) and with a 5-minute recirculation (right) 
during storage. 
 
For extrudates containing 50% CCX some crystals could be observed from d0 (Fig 61). At d30 
a visual increase could be observed. The non-reciculated samples did not properly let the light 
penetrate the sample due to the opaque nature of the strand. However, some light can be 
observed indicating possible thick layer of crystals. However, the Raman does not observe 
crystals in any of the samples. The 5min samples however clearly show some crystals on the 
PLM. It is difficult to quantify the crystallinity of the samples using PLM and more supporting 
data is required. It can be discussed whether Raman is a suitable method for CCX:Soluplus 
extrudates. It would be desirable to combine Raman with other analytical methods such as X-
ray powder diffraction and infrared spectroscopy.  
A test extrusion of 50% CCX at 130ºC was also done and kept at the same storage conditions. 
The Raman data of the samples also show amorphous content. By comparing the PLM pictures 
with the 50% CCX at 120ºC you can still see crystals in the pictures. Whether there are more 
or less crystalline CCX in the extrudates at different temperatures is difficult to determine due 
to lack of scaling and microscope settings. It would indicate though that a 5 minute recirculation 
of the API-polymer melt would increase the amount of amorphous CCX in the samples. As 
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with the extrudates containing NAP it would be desirable to have more analytical methods 
available such as XRPD and IR-spectroscopy. These methods were unfortunately not available 
during this research. 
 
Figure 61 PLM of 50% CCX prepared by HME without recirculation and with a 5-minute recirculation during 
storage. Process temperature 120°C (two left columns) and 130°C (two right columns) 
 
By comparing the solid dispersions prepared by either HME VCM significant differences can 
be seen when comparing rheological properties. Especially at higher API contents the VCM 
fails to produce amorphous API in the same extent as HME. This could be expected due to the 
lack of mixing and of shear forces in the VCM. The pressure inside the VCM helps to form 
compact API-polymer disks with little to no air entrapment, however the disks tend to be non-
homogenous with drug rich compartments of crystalline API. This was apparent at when using 
the same process temperature for both methods. When heating the VCM above the melting 
temperature of the API, a significant increase in amorphisation could be observed. These high 
process temperatures are not possible in the extruder for the selected API-polymer mixtures due 
to risk of degradation of the API and the very low viscosity of the melt at higher temperatures 
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7 Discussion 
 
The solubility determinations using Flory-Huggins correlate with the extrudates produced by 
HME. The solubility at 120°C was lower for CCX compared with NAP. This can be observed 
as the extrudates containing CCX are opaque indicating possible crystalline CCX within the 
polymer matrix. When increasing the extrusion temperature, the extrudate became clearer, 
indicating that more of the CCX had dissolved into the polymer. The Flory-Huggins data gives 
a good estimation of solubility and can be used to estimate initial drug load. Choosing 
parameters within the solubility limits can help in producing stable ASD’s. Due to the mixing 
within the extruder the solubility can be higher compared to the estimation by Flory-Huggins. 
For VCM the solubility of the API seems to be lower compared to HME which can be explained 
by the lack of mixing and shear forces in the VCM-tool. 
 
By visually examining the extrudates using PLM, some crystals can be observed in all the 
prepared VCM disks. Crystals were also observed in all disks prepared from extrudates 
produced initially by HME. The results are summarized in Table 7. Due to lack of permanent 
settings and magnification on the PLM, a crude quantification was chosen. The PLM data was 
categorised as no crystals, some crystals or crystals. The PLM data was compared with Raman 
data categorized as crystalline or amorphous. For NAP the difference in crystallinity between 
the HME and VCM is not evident. At 50% NAP content the Raman data shifts somewhat 
towards crystalline but no conclusive data can be obtained. For CCX a clear difference can be 
observed already at 10% CCX content where the VCM fails to amorphise CCX in the same 
extent as HME. The Raman data supports the PLM by indicating crystalline content in both 
30% and 50% CCX samples prepared by VCM while all the samples prepared by HME shifts 
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Table 7 Summary of PLM and Raman data. Crystallinity of PLM categorised into no crystals – some crystals – 
crystals. Raman data categorised as amorphous - Crystalline 
Sample PLM Raman 
HME NAP 10% 0min some crystals Amorphous 
HME NAP 10% 5min some crystals Amorphous 
MP NAP 10%  some crystals Amorphous 
HME NAP 30% 0min some crystals Amorphous 
HME NAP 30% 5min some crystals Amorphous 
MP NAP 30% crystals Amorphous 
HME NAP 50% 0min crystals Amorphous 
HME NAP 50% 5min crystals Amorphous 
MP NAP 50% crystals Amorphous/Crystalline 
HME CCX 10% 0min some crystals Amorphous 
HME CCX 10% 5min 
no crystals/some 
crystals Amorphous 
MP CCX 10%  crystals Amorphous 
HME CCX 30% 0min some crystals Amorphous 
HME CCX 30% 5min some crystals Amorphous 
MP CCX 30% crystals Crystalline 
HME CCX 50% 0min crystals Amorphous 
HME CCX 50% 5min crystals Amorphous 
MP CCX 50% crystals Crystalline 
 
 
When comparing the PLM and Raman results of the HME extrudates turned into VCM 
(HME+VCM) disks with the data obtained from the extruded strands during the stability study 
(Table 8), it would appear as the strands containing either NAP or CCX would have a lower 
crystalline content comparing with the HME+VCM disks. It can be discussed whether this is 
due to sampling error and PLM settings, or if some recrystallization of the extrudates occur 
during the disk preparation using VCM. The flat surface of the disks compared with the round 
shape of the extrudates can affect both the PLM and Raman data obscuring some of the 
crystalline content inside the extrudates.     
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Table 8 Summary of PLM and Raman data for extrudates during stability study. Crystallinity of PLM categorised 
into no crystals – some crystals – crystals. Raman data categorised as amorphous - Crystalline 
  Day 0 Day 0 Day 30 Day 30 Day 60 Day 60 
Sample PLM Raman PLM Raman PLM Raman 
























HME NAP 30% 
5min 
no 
crystals Amorphous - Amorphous 
some 
crystals Amorphous 
HME NAP 50% 
0min 
some 
crystals Amorphous crystals Crystalline crystals Crystalline 
HME NAP 50% 
5min 
some 
crystals Amorphous crystals Crystalline crystals Crystalline 
















HME CCX 30% 
0min 
some 
crystals Amorphous crystals Amorphous crystals Amorphous 








HME CCX 50% 
0min 
some 
crystals Amorphous crystals Amorphous crystals Amorphous 
HME CCX 50% 
5min 
some 
crystals Amorphous crystals Amorphous crystals Amorphous 
HME CCX 50% 
130C 0min crystals Amorphous crystals Amorphous   Amorphous 









From both the PLM and Raman data it would appear that CCX has a lower ability to form 
ASD’s with Soluplus when compared to NAP. The rheological and DSC data also show an 
increased plasticization and decrease in 𝑇𝑔 with increased NAP content even at 50%. The Flory-
Huggins estimation also suggest that over 50% of NAP should be able to solubilise in Soluplus. 
The rheological and DSC data for CCX does not show the same magnitude of 𝑇𝑔 reduction. 
Especially at higher CCX content, the viscosity and 𝑇𝑔 of the melt increases. This can be due 
to residual CCX crystals increasing the viscosity of the melt  
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The results support the Flory-Huggins model, suggesting that solubility determination can be 
used as a first screening method for optimal drug content for the chosen polymer. It can also be 
used to find the optimal polymer for the chosen API by preparing DSC samples containing 
different polymers. VCM and rheology can give further information of the melt properties of 
the API-polymer melt, assisting in choosing optimal process parameters such as temperature. 
It is worth nothing that VCM, due to lack of shear force and mixing does not have the same 
amorphising ability as HME. VCM still offers a rapid, cost-effective sample preparation as an 
initial screening tool before moving towards small scale extrusions. 
PLM due to its offline and time-consuming nature is not an optimal analytical tool for 
continuous manufacturing processes such as HME. PLM still offers great supporting data with 
a low limit of detection for crystalline residue as the PLM detected crystals when the Raman 
did not. Still, when optimised Raman can be used as a in-line analytical tool due to its rapid, 
non-destructive nature. For Raman optimal software containing data-processing is required. 
Raman. Raman can also be supported by further analytical methods such as X-ray powder 
diffraction and infrared spectroscopy to give a better understanding of the drug-polymer melts 
and the interaction of the materials within.   
This thesis has investigated the use of VCM as a screening tool for HME. Even though VCM 
appears to have a lower ability to form ASD’s compared to HME, especially at higher drug 
contents, it can still be a viable tool in initial assessment of melt properties. Based on the data 
obtained a flow chart was made depicting the process from raw materials to downstream 
processing (Fig. 62). After chosen API and polymer a solubility determination should be done 
to determine solubility of the API in the chosen polymer. Based on the results test formulations 
can be produced using VCM and rheological analysis. The resulting solid dispersions can be 
analysed for confirming amorphisity. After narrowing down to a few possible formulations, 
small scale extrusions can be made using lab-scale extrusions to save material costs and time. 
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Figure 62 Flow chart containing a suggestion for screening of ASD melt processability and formulation for HME 
 
PAT-tools and offline analytical methods can be used to confirm amorphisity and evaluate 
processability of the formulation. HME enables relatively easy upscaling and with modulated 
extruders there is room for customisation. After screening and determination of optimal 
formulation and process conditions HME can be used to continuously produce ASD’s ready for 
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8 Conclusions 
 
As amorphous solid dispersions can increase the solubility and thus bioavailability of poorly 
soluble drug, preparation of solid dispersions is an interesting prospect in the pharmaceutical 
field requiring further research. Hot-melt extrusion appears to be a viable method for 
preparation of solid dispersions and can produce continuously reducing time and cost of 
production. Vacuum compression moulding due to its efficient sample preparation can be used 
as a screening tool for HME formulations. Combined with rheological analysis and solubility 
estimation an understanding of the drug-polymer melt can be obtained before moving to small-
scale extrusions and final formulation optimisation, saving both time and resources. VCM 
should still be used with consideration when predicting melt properties of melt extrudates, 
especially at higher drug loads due to the lack of mixing and shear forces having a lower ability 
to form ASD’s compared with HME.  
However, with limited analytical methods available, it was difficult to determine the actual 
crystalline content in the samples. By adding methods such as X-ray powder diffraction and 
infrared spectroscopy a better understanding of the drug-polymer melts can be made.  Solubility 
estimation using the Flory-Huggins model is also a cost-effective tool for assessing the 
solubility of the drug in the chosen polymer, as oversaturation can increase the risk of 
recrystallization within the polymer matrix.  
Polarized light microscopy revealed crystals in samples that were determined amorphous by 
Raman spectroscopy. The limit of detection and optimal analytical tools for process control of 
ASD’s needs to be ensured. 
Overall, both solubility estimation and VCM combined with rheological analysis can provide 
efficient tools when screening for optimal formulation and process parameters for Hot-melt 
extrusion  
8.1 Future perspectives 
 
In this study the extrudates were characterized by a range of analytical techniques. 
Incorporation of process analytical technology in the manufacturing process would enable for 
continuous characterization of extrudates in-line produced by continuous manufacturing. 
Addition of analytical methods such as X-ray powder diffraction and infrared spectroscopy as 
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supplement to Raman and PLM, could give a further understanding of the characteristics of 
solid dispersions. An optimal tool with a low limit of detection for crystalline content should 
be optimized for the desired drug-polymer melts and if possible incorporated in the continuous 
manufacturing line as a process analytical technology tool.  
The effect of process temperature was only briefly touched in this thesis and should be studied 
more. The appearance of the extrudates of celecoxib changed from opaque to clear by a 10ºC 
increase of extrusion temperature and should be investigated further. Also, other process 
parameters including screw speed and melt pressure can influence the extrudates and should be 
evaluated. PLM indicated that some residual crystals could be found in most of the samples.  
Most of the sample extrudates also showed some crystallinity in polarized light microscopy and 
thus an evaluation of increased recirculation time would be of interest. By looking at the 
solubility predictions of the model compound naproxen in Soluplus, a higher solubility can be 
observed than the used ratios in this study. However especially the high drug content extrudates 
showed some crystallinity initially and already after 30 days of storage at 95% relative humidity 
seemed to have recrystallized significantly. It would be interesting to see how increase of time 
in the extruder at elevated temperature and shear forces would affect the extrudates. Liquid 
chromatography could be used to assess degradation of the materials. 
Rheology is utilized a lot in the food industry but has not found widespread interest in the 
pharmaceutical industry. By using standardized rheological testing methods, it can be possible 
to predict the processability of compounds and polymers. The use of rheology as a screening 
tool should further be investigated and further optimization should be done. The many benefits 
of rheology have been investigated and discussed in literature and should be incorporated more 
into the pharmaceutical industry.  
This thesis has focused on producing solid dispersions and evaluating the melt processability 
of the drug-polymer melts in order to produce oral dosage forms with increased bioavailability. 
To ensure improved dissolution and bioavailability, dissolution testing and release studies 
should be done on the produced extrudates.  
For commercial solid dispersions it is of crucial importance that the produced solid dispersions 
are completely amorphous and no residual crystals of API can be found. For this, reliable 
analytical tools should be evaluated. The possibility of continuous manufacturing requires 
continuous analytical tools both in-line and off-line to ensure product quality. Once a suitable 
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production method for an amorphous solid dispersion has been found, the product and process 
should be validated and all the important parameters be investigated i.e. temperature, drug 
content, process speed and settings. This is of course routine for all types of drug manufacturing 
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Appendix 
 
A.1 TGA  
 
Figure 63 TGA Soluplus 
 
Figure 64 TGA NAP 
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Figure 65 TGA CCX 
  
 




Figure 66 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. Soluplus standard 
Soluplus std
Exo Up
Min y: -5,98892e-4 W / (g.°C)
At x: 77,981 °C
At x: 74,240 °C
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Figure 67 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME  CCX:Soluplus 10:90 0min recirculation   
 
Figure 68 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME  CCX:Soluplus 10:90 5min recirculation   
HME 10%CCX 0min
Exo Up
Min y: -6,76005e-4 W / (g.°C)
At x: 79,303 °C
Min y: -6,03224e-4 W / (g.°C)
At x: 77,615 °C
Min y: -1,87839e-3 W / (g.°C)
At x: 111,038 °C
HME 10% CCX 5min
Exo Up
Min y: -7,09211e-4 W / (g.°C)
At x: 79,703 °C
Min y: -5,72893e-4 W / (g.°C)
At x: 71,931 °C
Min y: -8,27150e-4 W / (g.°C)
At x: 107,487 °C
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Figure 69 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME  CCX:Soluplus 30:70 0min recirculation   
 
Figure 70 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME  CCX:Soluplus 30:70 5min recirculation   
HME 30% CCX 0min
Exo Up
Min y: -1,38756e-3 W / (g.°C)
At x: 120,731 °C
Min y: -7,47161e-4 W / (g.°C)
At x: 79,132 °C
Min y: -6,05844e-4 W / (g.°C)
At x: 72,245 °C
HME 30% CCX 5min
Exo Up
Min y: -6,35206e-4 W / (g.°C)
At x: 87,050 °C
Min y: -3,07678e-3 W / (g.°C)
At x: 109,184 °C
Min y: -7,52771e-4 W / (g.°C)
At x: 77,529 °C
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Figure 71 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME  CCX:Soluplus 50:50 0min recirculation   
 
Figure 72 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME  CCX:Soluplus 50:50 5min recirculation   
HME 50% CCX 0min
Exo Up
Min y: -6,79740e-4 W / (g.°C)
At x: 75,437 °C
Min y: -8,53663e-4 W / (g.°C)
At x: 74,334 °C
Min y: -5,30646e-4 W / (g.°C)
At x: 120,351 °C
HME 50% CCX 5min
Exo Up
Min y: -1,61356e-3 W / (g.°C)
At x: 109,517 °CMin y: -6,94251e-4 W / (g.°C)
At x: 75,489 °C
Min y: -8,38828e-4 W / (g.°C)
At x: 80,973 °C
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Figure 73 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. MeltPrep  CCX:Soluplus 10:90 15min recirculation   
 
Figure 74 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. MeltPrep  CCX:Soluplus 30:70 15min recirculation   
MP 10% 15min
Exo Up
Min y: -8,68038e-4 W / (g.°C)
At x: 75,962 °C
Min y: -7,26323e-4 W / (g.°C)
At x: 75,209 °C
Min y: -5,22436e-4 W / (g.°C)
At x: 146,203 °C
MP 30% CCX 15min
Exo Up
Min y: -9,39751e-4 W / (g.°C)
At x: 76,140 °C
Min y: -7,00101e-4 W / (g.°C)
At x: 70,676 °C
Min y: -1,43961e-3 W / (g.°C)
At x: 159,230 °C
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Figure 75 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. Physical mixture of raw materials CCX:Soluplus 10:90 
 
Figure 76 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. Physical mixture of raw materials CCX:Soluplus 30:70 
Physmix 10% CCX 
Exo Up
Min y: -1,26814e-3 W / (g.°C)
At x: 84,526 °C
Min y: -2,20087e-3 W / (g.°C)
At x: 160,769 °C
Min y: -6,35906e-4 W / (g.°C)
At x: 74,521 °C
Min y: -5,05086e-4 W / (g.°C)
At x: 140,936 °C
Physmix 30% CCX 
Exo Up
Min y: -4,38886e-4 W / (g.°C)
At x: 75,053 °C
Min y: -6,55002e-4 W / (g.°C)
At x: 70,353 °C
Min y: -0,0174206 W / (g.°C)
At x: 160,052 °C
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Figure 77 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. Physical mixture of raw materials CCX:Soluplus 50:50 
 
Figure 78 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME NAP:Soluplus 10:90 0min recirculation 
Physmix 50% CCX
Exo Up
Min y: -0,0138196 W / (g.°C)
At x: 108,105 °C
Min y: -1,84598e-3 W / (g.°C)
At x: 59,740 °C
Min y: -0,0448355 W / (g.°C)
At x: 158,745 °C
HME 10% NAP 0min
Exo Up
Min y: -5,93321e-4 W / (g.°C)
At x: 61,987 °C
Min y: -5,80968e-4 W / (g.°C)
At x: 66,104 °C
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Figure 79 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME NAP:Soluplus 10:90 5min recirculation 
 
Figure 80 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME NAP:Soluplus 30:70 0min recirculation 
HME 10% NAP 5min
Exo Up
Min y: -5,86743e-4 W / (g.°C)
At x: 67,522 °C
Min y: -7,47137e-4 W / (g.°C)
At x: 66,282 °C
Min y: -2,17522e-3 W / (g.°C)
At x: 153,214 °C
HME 30% NAP 0min
Exo Up
Min y: -9,83944e-4 W / (g.°C)
At x: 54,383 °C
Min y: -1,01211e-3 W / (g.°C)
At x: 51,781 °C
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Figure 81 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME NAP:Soluplus 30:70 5min recirculation 
HME 30% NAP 5min
Exo Up
Min y: -9,30341e-4 W / (g.°C)
At x: 52,619 °C
Min y: -9,61567e-4 W / (g.°C)
At x: 46,472 °C
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Figure 82 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME NAP:Soluplus 50:50 0min recirculation
 
Figure 83 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. HME NAP:Soluplus 50:50 5min recirculation 
HME 50% NAP 0min
Exo Up
Min y: -1,03097e-3 W / (g.°C)
At x: 44,094 °C
Min y: -1,06569e-3 W / (g.°C)
At x: 37,915 °C
HME 50% NAP 5min
Exo Up
Min y: -1,09410e-3 W / (g.°C)
At x: 36,774 °C
Min y: -1,00275e-3 W / (g.°C)
At x: 37,780 °C
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Figure 84 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. MeltPrep NAP:Soluplus 10:90 15min 
 
Figure 85 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. MeltPrep NAP:Soluplus 30:70 15min 
MP 10% NAP 15min
Exo Up
Min y: -7,91682e-4 W / (g.°C)
At x: 50,963 °C
Min y: -9,28172e-4 W / (g.°C)
At x: 59,980 °C
MP 30% NAP 15min
Exo Up
Min y: -8,96624e-4 W / (g.°C)
At x: 39,089 °C
Min y: -1,20961e-3 W / (g.°C)
At x: 43,229 °C Min y: -9,95145e-4 W / (g.°C)
At x: 117,328 °C
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Figure 86 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. MeltPrep NAP:Soluplus 50:50 15min
 
Figure 87 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 
inflection point. Physical mixture of raw materials NAP:Soluplus 10:90 
MP 50% NAP 15min
Exo Up
Min y: -8,22349e-4 W / (g.°C)
At x: 34,432 °C
Min y: -1,20090e-3 W / (g.°C)
At x: 32,695 °C
Min y: -2,24397e-3 W / (g.°C)
At x: 116,083 °C
Physmix 10% NAP
Exo Up
Min y: -4,77525e-4 W / (g.°C)
At x: 74,561 °C
Min y: -5,25795e-4 W / (g.°C)
At x: 70,124 °C
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Figure 88 Reversing heat flow of Ramp 2 (blue) & Ramp 3 (green) with corresponding derrivatives and Tg 








Min y: -1,34310e-3 W / (g.°C)
At x: 54,993 °C
Min y: -1,48226e-3 W / (g.°C)
At x: 112,656 °C
Min y: -4,18492e-4 W / (g.°C)
At x: 73,132 °C
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Figure 89 Melting point determination of NAP 
 
Figure 90 Melting point depression of NAP:Soluplus mixtures 
16112017nap_std_2Discovery DSC
Exo Up
Solubility Naproxen in Soluplus
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Figure 91 Melting point determination of CCX 
 
Figure 92 Melting point depression of CCX:Soluplus mixtures 
CCX RAW
Exo Up
Solubility Celecoxib in Soluplus
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The calculation sheet for the solubility determination using the Flory-Huggins model can be requested 




Figure 93 Frequency sweep 10% NAP HME 0min 
HME_naproxen_soluplus_10_90_120C_0min_MP_100C15minFreqSweep(JA)09-11-2017
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Figure 94 Frequency sweep 10% NAP HME 5min 
HME_naproxen_soluplus_10_90_120C_5min_MP_100C15minFreqSweep(JA)07-11-2017
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Figure 95 Frequency sweep 10% NAP VCM 15min 
naproxen_soluplus_10_90_120C_15min_2FreqSweep(JA)03-11-2017
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Figure 96 Frequency sweep 30% NAP HME 0min 
HME_naproxen_soluplus_30_70_120C_0min_MP_100C15min3FreqSweep(JA)09-11-2017
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Figure 97 Frequency sweep 30% NAP HME 5min 
HME_naproxen_soluplus_30_70_120C_5min_MP_100C15minFreqSweep(JA)07-11-2017
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Figure 98 Frequency sweep 30% NAP VCM 15min 
naproxen_soluplus_30_70_120C_15min2FreqSweep(JA)03-11-2017
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Figure 99 Frequency sweep 50% NAP HME 0 min 
HME_naproxen_soluplus_50_50_120C_0min_MP_100C15minFreqSweep(JA)09-11-2017
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Figure 100 Frequency sweep 50% NAP HME 5 min 
HME_naproxen_soluplus_50_50_120C_5min_MP_100C15min2FreqSweep(JA)07-11-2017
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Figure 101 Frequency sweep 50% NAP VCM 15min 
naproxen_soluplus_50_50_120C_15min2FreqSweep(JA)06-11-2017
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Figure 102 Frequency sweep 10% CCX  HME 0 min 
HME_celecoxib_soluplus_10_90_120C_0min_MP_100C15min1FreqSweep(JA)30-11-2017
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Figure 103 Frequency sweep 10% CCX  HME 5 min 
HME_celecoxib_soluplus_10_90_120C_5min_MP_100C15min1FreqSweep(JA)30-11-2017
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Figure 104 Frequency sweep 10% CCX  VCM 15min 
Meltprep_celecoxib_soluplus_10_90_120C_15min1FreqSweep(JA)30-11-2017
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Figure 105 Frequency sweep 30% CCX  HME 0 min 
HME_celecoxib_soluplus_30_70_120c50rpm0min_mp_100C_15min2FreqSweep(JA)30-11-2017
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Figure 106 Frequency sweep 30% CCX  HME 5 min 
HME_celecoxib_soluplus_30_70_120c50rpm5min_mp_100C_15min2FreqSweep(JA)30-11-2017
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Figure 107 Frequency sweep 30% CCX  VCM 15min 
celecoxib_soluplus_30_70_pm_mp_120C_15min2FreqSweep(JA)01-12-2017
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Figure 108 Frequency sweep 50% CCX  HME 0 min 
HME_celecoxib_soluplus_50_50_120c50rpm0min_mp_100C_15min2FreqSweep(JA)01-12-2017
 
Page 120 of 132 
 
Figure 109 Frequency sweep 50% CCX  HME 5 min 
HME_celecoxib_soluplus_50_50_120c50rpm5min_mp_100C_15min1FreqSweep(JA)01-12-2017
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Figure 111 Temperature sweep CCX 10% 
CCX_SP_10_90_tempsweep_pm
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Figure 112Temperature sweep CCX 30% 
CCX_SP_30_70_tempsweep_pm_MP100c15min
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Figure 113 Temperature sweep NAP 10% 
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Figure 116 SNV corrected Raman spectra of NAP:Soluplus solid dispersions. Coloured according to process 
temperature. 120°C (blue) 130°C (red) and 170°C (yellow). Physical mixtures for reference(green) 
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Figure 117 SNV corrected Raman spectra of NAP:Soluplus solid dispersions. Coloured according to NAP 
content. Soluplus std (green), 10% (brown), 25%(red), 30% (lime) 50% (blue) 100% crystalline NAP (purple)  
 
Figure 118 Loadings plot of the second component (PC-2) 31,2% explained variance 
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Figure 119 PCA of NAP:Soluplus. Coloured according to recirculation time. No recirculation time, HME (green) 5 
minute recirculation time HME (orange) 15minute VCM (red). Physical mixtures as reference (blue) 
  
 




Figure 120 PCA of NAP:Soluplus. Coloured according to recirculation time 
 
Figure 121 SNV corrected Raman spectra of CCX:Soluplus solid dispersions during storage. Coloured by drug 
content. 
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Figure 122 Figure 43 SNV corrected Raman spectra of CCX:Soluplus solid dispersions. Coloured according to 
CCX content. Soluplus std(yellow), 10% (orange), 25% (teal), 30% (green), 50% (blue). 100% crystalline std (red) 
 
Figure 123 SNV corrected Raman spectra of CCX:Soluplus solid dispersions. Coloured according to recirculation 
time. No recirculation (red) 5 minute recirculation (blue) 10 minute MeltPrep (oragen) 15 minute MeltPrep(green). 
Physical mixtures for reference (grey/No ID) 
 
Page 131 of 132 
 
Figure 124 Loadings plot of the second component (PC-2) 20,7% explained variance 
 
Figure 125 PCA of CCX:Soluplus. Coloured according to recirculation time. No recirculation, HME (red), 5min 
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